

# Laurent Peyrin-Biroulet

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/8395548/laurent-peyrin-biroulet-publications-by-year.pdf>  
**Version:** 2024-04-05

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.  
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

644 papers	31,468 citations	87 h-index	161 g-index
707 ext. papers	40,575 ext. citations	6.1 avg, IF	7.76 L-index

#	Paper	IF	Citations
644	Evolution of IL-23 Blockade in Inflammatory Bowel Disease.. <i>Journal of Crohn's and Colitis</i> , <b>2022</b> , 16, ii1-ii2.	2.5	
643	DOP90 Efficacy of the treat-to-target approach in modifying disease course with ustekinumab in patients with moderate-to-severe Crohn's Disease: Results from the STARDUST trial. <i>Journal of Crohn's and Colitis</i> , <b>2022</b> , 16, i132-i134	1.5	
642	OP39 Shorter disease duration is associated with better outcomes in patients with moderately to severely active Crohn's Disease treated with risankizumab: Results from the phase 3 ADVANCE, MOTIVATE, and FORTIFY studies. <i>Journal of Crohn's and Colitis</i> , <b>2022</b> , 16, i045-i048	1.5	0
641	OP07 Exploring disease control by combining clinical, biological, and health-related quality of life remission with endoscopic improvements among Ulcerative Colitis patients treated with filgotinib: A post-hoc analysis from the SELECTION trial. <i>Journal of Crohn's and Colitis</i> , <b>2022</b> , 16, i007-i008	1.5	0
640	Ustekinumab in Crohn's Disease: New Data for Positioning in Treatment Algorithm.. <i>Journal of Crohn's and Colitis</i> , <b>2022</b> , 16, ii30-ii41	1.5	3
639	Perspectives on Subcutaneous Infliximab for Rheumatic Diseases and Inflammatory Bowel Disease: Before, During, and After the COVID-19 Era.. <i>Advances in Therapy</i> , <b>2022</b> , 1	4.1	1
638	P521 Correlation of histological assessment of mucosal healing with long-term clinical and patient-reported outcomes in patients with moderately to severely active ulcerative colitis treated with upadacitinib: results from the Phase 3 U-ACHIEVE maintenance trial. <i>Journal of Crohn's and Colitis</i> , <b>2022</b> , 16, i476-i477	1.5	0
637	P331 Composite outcomes in Crohn's disease: a systematic review and meta-analysis of observational studies. <i>Journal of Crohn's and Colitis</i> , <b>2022</b> , 16, i349-i350	1.5	
636	Letter: treatment with subcutaneous CT-P13 in Crohn's disease patients with intravenous infliximab failure.. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2022</b> , 55, 508-509	6.1	1
635	P491 Efficacy and safety outcomes of long-term treatment with filgotinib 200 mg among patients with Ulcerative Colitis: An interim analysis of SELECTIONLTE. <i>Journal of Crohn's and Colitis</i> , <b>2022</b> , 16, i456-i457	1.5	0
634	P267 Milan Ultrasound Criteria are accurate in assessing endoscopic remission and treatment response in patients with ulcerative colitis. <i>Journal of Crohn's and Colitis</i> , <b>2022</b> , 16, i306-i307	1.5	
633	P230 Ultrasonography-based and Magnetic Resonance-based Lhann Index: two sides of the same coin. <i>Journal of Crohn's and Colitis</i> , <b>2022</b> , 16, i278-i279	1.5	1
632	P517 Re-treatment with filgotinib in patients with Ulcerative Colitis following treatment interruption: Analysis of the SELECTION and SELECTIONLTE studies. <i>Journal of Crohn's and Colitis</i> , <b>2022</b> , 16, i473-i474	1.5	0
631	Higher vs Standard Adalimumab Induction Dosing Regimens and 2 Maintenance Strategies: Randomized SERENE CD Trial Results.. <i>Gastroenterology</i> , <b>2022</b> ,	13.3	3
630	Therapeutic drug monitoring of biologics in inflammatory bowel disease: unmet needs and future perspectives.. <i>The Lancet Gastroenterology and Hepatology</i> , <b>2022</b> , 7, 171-185	18.8	4
629	JAK inhibitors in crohn's disease: ready to go?. <i>Expert Opinion on Investigational Drugs</i> , <b>2022</b> , 1-17	5.9	
628	Higher vs Standard Adalimumab Induction and Maintenance Dosing Regimens for Treatment of Ulcerative Colitis: SERENE UC Trial Results.. <i>Gastroenterology</i> , <b>2022</b> ,	13.3	2

627	Predictive value of Milan ultrasound criteria in ulcerative colitis: A prospective observational cohort study.. <i>United European Gastroenterology Journal</i> , <b>2022</b> ,	5.3	1
626	Prevalence of Self-Reported Venous Thromboembolism and Cardiovascular Risk Factors in Patients with Ulcerative Colitis: The GETAID FOCUS Study.. <i>Digestive Diseases and Sciences</i> , <b>2022</b> , 1	4	0
625	Ranking treatments in the network meta-analysis should consider the certainty of evidence - Authors' reply.. <i>The Lancet Gastroenterology and Hepatology</i> , <b>2022</b> , 7, 288	18.8	
624	Iron Deficiency in Patients with Inflammatory Bowel Diseases: A Prospective Multicenter Cross-Sectional Study.. <i>Digestive Diseases and Sciences</i> , <b>2022</b> , 1	4	0
623	Difficult-to-treat inflammatory bowel disease: results from a global IOIBD survey.. <i>The Lancet Gastroenterology and Hepatology</i> , <b>2022</b> , 7, 390-391	18.8	1
622	Corticosteroid-free efficacy and safety outcomes in patients receiving tofacitinib in the OCTAVE Sustain maintenance study.. <i>Therapeutic Advances in Gastroenterology</i> , <b>2022</b> , 15, 17562848221090834	4.7	
621	Is it time to include older adults in inflammatory bowel disease trials? A call for action. <i>The Lancet Healthy Longevity</i> , <b>2022</b> , 3, e356-e366	9.5	1
620	Composite outcomes in observational studies of Crohn's disease: a systematic review and meta-analysis. <i>Therapeutic Advances in Gastroenterology</i> , <b>2022</b> , 15, 175628482210927	4.7	
619	Knowledge of 5-aminosalicylic acid nephrotoxicity and adherence to kidney function monitoring of patients with inflammatory bowel disease. <i>European Journal of Gastroenterology and Hepatology</i> , <b>2021</b> , 33, 1148-1152	2.2	1
618	Location but Not Severity of Endoscopic Lesions Influences Endoscopic Remission Rates in Crohn's Disease: A Post Hoc Analysis of TAILORIX. <i>American Journal of Gastroenterology</i> , <b>2021</b> , 116, 134-141	0.7	5
617	Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial. <i>The Lancet Gastroenterology and Hepatology</i> , <b>2021</b> ,	18.8	5
616	Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis. <i>The Lancet Gastroenterology and Hepatology</i> , <b>2021</b> ,	18.8	12
615	Magnetic Resonance Elastography for Assessing Fibrosis in Patients with Crohn's Disease: A Pilot Study. <i>Digestive Diseases and Sciences</i> , <b>2021</b> , 1	4	1
614	Steroid-Free Deep Remission At One Year Does Not Prevent Crohn's Disease Progression: Long-Term Data From the TAILORIX Trial. <i>Clinical Gastroenterology and Hepatology</i> , <b>2021</b> ,	6.9	3
613	Long-Term Overconsumption of Fat and Sugar Causes a Partially Reversible Pre-inflammatory Bowel Disease State. <i>Frontiers in Nutrition</i> , <b>2021</b> , 8, 758518	6.2	2
612	Etrolizumab versus infliximab for the treatment of moderately to severely active ulcerative colitis (GARDENIA): a randomised, double-blind, double-dummy, phase 3 study. <i>The Lancet Gastroenterology and Hepatology</i> , <b>2021</b> ,	18.8	7
611	Kidney function monitoring in inflammatory bowel disease: The MONITORED consensus. <i>Digestive and Liver Disease</i> , <b>2021</b> ,	3.3	2
610	Tumour necrosis factor inhibitors in inflammatory bowel disease: the story continues.. <i>Therapeutic Advances in Gastroenterology</i> , <b>2021</b> , 14, 17562848211059954	4.7	3

609	Evolving short- and long-term goals of management of IBD: getting it right, making it last.. <i>Gastroenterology</i> , <b>2021</b> ,	13.3	1
608	'Treat to Target' in Mild to Moderate Ulcerative Colitis: Evidence to Support this Strategy. <i>Current Drug Targets</i> , <b>2021</b> , 22, 117-125	3	2
607	Bariatric Surgery in Patients With Inflammatory Bowel Disease: A Case-Control Study from the GETAID. <i>Inflammatory Bowel Diseases</i> , <b>2021</b> ,	4.5	1
606	Biosimilar-to-Biosimilar Switching: What is the Rationale and Current Experience?. <i>Drugs</i> , <b>2021</b> , 81, 1859-1879	12.7	3
605	Efficacy of Biologic Drugs in Short-Duration Versus Long-Duration Inflammatory Bowel Disease: A Systematic Review and an Individual-Patient Data Meta-Analysis of Randomized Controlled Trials. <i>Gastroenterology</i> , <b>2021</b> ,	13.3	8
604	Thrombosis in IBD in the Era of JAK Inhibition. <i>Current Drug Targets</i> , <b>2021</b> , 22, 126-136	3	1
603	Maximizing the diagnostic information from biopsies in chronic inflammatory bowel diseases: recommendations from the Erlangen International Consensus Conference on Inflammatory Bowel Diseases and presentation of the IBD-DCA score as a proposal for a new index for histologic activity assessment in ulcerative colitis and Crohn's disease. <i>Virchows Archiv Fur Pathologische Anatomie</i>	5.1	8
602	The IBD-disk Is a Reliable Tool to Assess the Daily-life Burden of Patients with Inflammatory Bowel Disease. <i>Journal of Crohn's and Colitis</i> , <b>2021</b> , 15, 766-773	1.5	1
601	Ustekinumab for Extra-intestinal Manifestations of Inflammatory Bowel Disease: A Systematic Literature Review. <i>Journal of Crohn's and Colitis</i> , <b>2021</b> , 15, 1236-1243	1.5	13
600	Histologic Features of Colon Biopsies (Geboes Score) Associated With Progression of Ulcerative Colitis for the First 36 Months After Biopsy. <i>Clinical Gastroenterology and Hepatology</i> , <b>2021</b> , 19, 2567-2576.e9	6.9	2
599	Treat to Target: The Role of Histologic Healing in Inflammatory Bowel Diseases: A Systematic Review and Meta-analysis. <i>Clinical Gastroenterology and Hepatology</i> , <b>2021</b> , 19, 1800-1813.e4	6.9	22
598	Combination Therapy Does Not Improve Rate of Clinical or Endoscopic Remission in Patients with Inflammatory Bowel Diseases Treated With Vedolizumab or Ustekinumab. <i>Clinical Gastroenterology and Hepatology</i> , <b>2021</b> , 19, 1366-1376.e2	6.9	22
597	Endoscopic balloon dilation of colorectal strictures complicating Crohn's disease: a multicenter study. <i>Clinics and Research in Hepatology and Gastroenterology</i> , <b>2021</b> , 45, 101561	2.4	2
596	Probe-based Confocal Laser Endomicroscopy for In Vivo Assessment of Histological Healing in Ulcerative Colitis: Development and Validation of the ENHANCE Index. <i>Journal of Crohn's and Colitis</i> , <b>2021</b> , 15, 994-999	1.5	2
595	Ethnic Differences in the Smoking-related Risk of Inflammatory Bowel Disease: A Systematic Review and Meta-analysis. <i>Journal of Crohn's and Colitis</i> , <b>2021</b> , 15, 1658-1678	1.5	0
594	New Paradigms to Help Decisions in Treatment Choice: Head to Head Trial of Biological Therapies in Inflammatory Bowel Diseases. <i>Current Drug Targets</i> , <b>2021</b> , 22, 370-378	3	
593	Efficacy and Safety of Tofacitinib in Ulcerative Colitis Based on Prior Tumor Necrosis Factor Inhibitor Failure Status. <i>Clinical Gastroenterology and Hepatology</i> , <b>2021</b> ,	6.9	4
592	Real-life pilot study on the impact of the telemedicine platform EasyMCI-MaMCI on quality of life and quality of care in patients with inflammatory bowel disease. <i>Scandinavian Journal of Gastroenterology</i> , <b>2021</b> , 56, 530-536	2.4	1

591	A15 EFFICACY AND SAFETY OF FILGOTINIB AS INDUCTION THERAPY FOR PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 2B/3 SELECTION STUDY. <i>Journal of the Canadian Association of Gastroenterology</i> , <b>2021</b> , 4, 18-20	0.5	4
590	Drug development for ulcerative proctitis: current concepts. <i>Gut</i> , <b>2021</b> , 70, 1203-1209	19.2	1
589	A17 EFFICACY AND SAFETY OF FILGOTINIB AS MAINTENANCE THERAPY FOR PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 2B/3 SELECTION STUDY. <i>Journal of the Canadian Association of Gastroenterology</i> , <b>2021</b> , 4, 21-23	0.5	5
588	Quality of Life and Work Productivity Improvements with Upadacitinib: Phase 2b Evidence from Patients with Moderate to Severe Crohn's Disease. <i>Advances in Therapy</i> , <b>2021</b> , 38, 2339-2352	4.1	1
587	Safety of S1P Modulators in Patients with Immune-Mediated Diseases: A Systematic Review and Meta-Analysis. <i>Drug Safety</i> , <b>2021</b> , 44, 645-660	5.1	4
586	Validation of the 'Inflammatory Bowel Disease-Distribution, Chronicity, Activity [IBD-DCA] Score' for Ulcerative Colitis and Crohn's Disease. <i>Journal of Crohn's and Colitis</i> , <b>2021</b> , 15, 1621-1630	1.5	4
585	Predictive Value of Bowel Ultrasound in Crohn's Disease: A 12-Month Prospective Study. <i>Clinical Gastroenterology and Hepatology</i> , <b>2021</b> ,	6.9	2
584	Patients' real-world experience with inflammatory bowel disease: A cross-sectional survey in tertiary care centres from the GETAID group. <i>Digestive and Liver Disease</i> , <b>2021</b> , 53, 434-441	3.3	
583	Histological Disease Activity Measured by the Nancy Index Is Associated with Long-term Outcomes in Patients with Ulcerative Colitis. <i>Journal of Crohn's and Colitis</i> , <b>2021</b> , 15, 1631-1640	1.5	2
582	Selecting End Points for Disease-Modification Trials in Inflammatory Bowel Disease: the SPIRIT Consensus From the IOIBD. <i>Gastroenterology</i> , <b>2021</b> , 160, 1452-1460.e21	13.3	15
581	STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD. <i>Gastroenterology</i> , <b>2021</b> , 160, 1570-1583	13.3	191
580	Reply. <i>Gastroenterology</i> , <b>2021</b> , 160, 1881	13.3	
579	International consensus on methodological issues in standardization of fecal calprotectin measurement in inflammatory bowel diseases. <i>United European Gastroenterology Journal</i> , <b>2021</b> , 9, 451-460	5.3	6
578	P383 Relationship between histo-endoscopic mucosal healing and baseline characteristics in patients with moderately to severely active Ulcerative Colitis receiving filgotinib in the phase 2b/3 SELECTION study. <i>Journal of Crohn's and Colitis</i> , <b>2021</b> , 15, S395-S396	1.5	0
577	DOP88 Effect of risankizumab on patient-reported outcomes in patients with Crohn's Disease who had an inadequate response or intolerance to conventional and/or biologic treatments: Results from phase 3 MOTIVATE and ADVANCE trials. <i>Journal of Crohn's and Colitis</i> , <b>2021</b> , 15, S119-S121	1.5	
576	DOP87 Disease clearance as a new therapeutic target in patients with Ulcerative Colitis: A multicenter retrospective cohort study. <i>Journal of Crohn's and Colitis</i> , <b>2021</b> , 15, S118-S119	1.5	0
575	Reply. <i>Gastroenterology</i> , <b>2021</b> , 160, 2223-2224	13.3	
574	Ustekinumab is more effective than azathioprine to prevent endoscopic postoperative recurrence in Crohn's disease. <i>United European Gastroenterology Journal</i> , <b>2021</b> , 9, 552-560	5.3	4

573	Inflammatory Bowel Disease and COVID-19 Vaccination: A Patients' Survey. <i>Digestive Diseases and Sciences</i> , <b>2021</b> , 1	4	9
572	OP36 Risankizumab therapy induces improvements in endoscopic endpoints in patients with Moderate-to-Severe Crohn's Disease: Results from the phase 3 ADVANCE and MOTIVATE studies. <i>Journal of Crohn's and Colitis</i> , <b>2021</b> , 15, S033-S034	1.5	0
571	P301 Ustekinumab improves health-related quality of life in patients with moderate-to-severe Crohn's disease: results up to Week 48 of the STARDUST trial. <i>Journal of Crohn's and Colitis</i> , <b>2021</b> , 15, S330-S331	1.5	1
570	Kidney function monitoring to prevent 5-aminosalicylic acid nephrotoxicity: What the gastroenterologist should know. <i>Digestive and Liver Disease</i> , <b>2021</b> , 53, 691-696	3.3	2
569	Selective Tyrosine Kinase 2 Inhibition for Treatment of Inflammatory Bowel Disease: New Hope on the Rise. <i>Inflammatory Bowel Diseases</i> , <b>2021</b> , 27, 2023-2030	4.5	8
568	Role of Cross-Sectional Imaging in Pediatric Inflammatory Bowel Disease. <i>Digestive Diseases and Sciences</i> , <b>2021</b> , 1	4	0
567	IBD goes home: from telemedicine to self-administered advanced therapies. <i>Expert Opinion on Biological Therapy</i> , <b>2021</b> , 1-13	5.4	0
566	Tofacitinib as salvage therapy for 55 patients hospitalised with refractory severe ulcerative colitis: A GETAID cohort. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2021</b> , 54, 312-319	6.1	1
565	Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b/3 double-blind, randomised, placebo-controlled trial. <i>Lancet, The</i> , <b>2021</b> , 397, 2372-2384	4.0	36
564	A Magnetic Resonance Imaging Index to Predict Crohn's Disease Postoperative Recurrence: The MONITOR Index. <i>Clinical Gastroenterology and Hepatology</i> , <b>2021</b> ,	6.9	6
563	Thiopurines: Use them or lose them? International survey on current and future use of thiopurines in inflammatory bowel disease. <i>Digestive and Liver Disease</i> , <b>2021</b> , 53, 1571-1579	3.3	0
562	Defining difficult-to-treat inflammatory bowel disease: why and how. <i>The Lancet Gastroenterology and Hepatology</i> , <b>2021</b> , 6, 520-522	18.8	2
561	Biobetters in patients with immune-mediated inflammatory disorders: An international Delphi consensus. <i>Autoimmunity Reviews</i> , <b>2021</b> , 20, 102849	13.6	3
560	A Practical Guide for Faecal Calprotectin Measurement: Myths and Realities. <i>Journal of Crohn's and Colitis</i> , <b>2021</b> , 15, 152-161	1.5	10
559	Risk of Late Postoperative Recurrence of Crohn's Disease in Patients in Endoscopic Remission After Ileocecal Resection, Over 10 Years at Multiple Centers. <i>Clinical Gastroenterology and Hepatology</i> , <b>2021</b> , 19, 1218-1225.e4	6.9	4
558	Shedding Light on Hemostasis in Patients With Inflammatory Bowel Diseases. <i>Clinical Gastroenterology and Hepatology</i> , <b>2021</b> , 19, 1088-1097.e6	6.9	11
557	Clinical Practice of Adalimumab and Infliximab Biosimilar Treatment in Adult Patients With Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , <b>2021</b> , 27, 106-122	4.5	6
556	Clinical guidelines for the management of inflammatory bowel disease: Update of a French national consensus. <i>Digestive and Liver Disease</i> , <b>2021</b> , 53, 35-43	3.3	9

555	Evolution of Endoscopic Lesions in Steroid-Refractory Acute Severe Ulcerative Colitis Responding to Infliximab or Cyclosporine. <i>Clinical Gastroenterology and Hepatology</i> , <b>2021</b> , 19, 1180-1188.e4	6.9	6
554	Point-of-Care Ultrasound in Inflammatory Bowel Disease. <i>Journal of Crohn's and Colitis</i> , <b>2021</b> , 15, 143-151.	5	6
553	Milan ultrasound criteria are accurate in assessing disease activity in ulcerative colitis: external validation. <i>United European Gastroenterology Journal</i> , <b>2021</b> , 9, 438-442	5.3	4
552	An Anti-migration Self-expandable and Removable Metal Stent for Crohn's Disease Strictures: A Nationwide Study From GETAID and SFED. <i>Journal of Crohn's and Colitis</i> , <b>2021</b> , 15, 521-528	1.5	6
551	Evolution of infliximab biosimilar in inflammatory bowel disease: from intravenous to subcutaneous CT-P13. <i>Expert Opinion on Biological Therapy</i> , <b>2021</b> , 21, 37-46	5.4	3
550	Crohn's Disease Only Visible on Small Bowel Capsule Endoscopy: A New Entity. <i>Digestive Diseases and Sciences</i> , <b>2021</b> , 66, 2712-2716	4	2
549	Characteristics of Lymphoma in Patients with Inflammatory Bowel Disease: A Systematic Review. <i>Journal of Crohn's and Colitis</i> , <b>2021</b> , 15, 827-839	1.5	6
548	Nocebo effect and biosimilars in inflammatory bowel diseases: what's new and what's next?. <i>Expert Opinion on Biological Therapy</i> , <b>2021</b> , 21, 47-55	5.4	3
547	Clinical, Endoscopic and Histological Outcomes in Induction of Moderate-to-Severe Ulcerative Colitis: A Systematic Review with Meta-Analysis. <i>Journal of Crohn's and Colitis</i> , <b>2021</b> , 15, 551-566	1.5	1
546	TNF Inhibitors and Risk of Malignancy in Patients with Inflammatory Bowel Diseases: A Systematic Review. <i>Journal of Crohn's and Colitis</i> , <b>2021</b> , 15, 840-859	1.5	11
545	Emerging treatment options for extraintestinal manifestations in IBD. <i>Gut</i> , <b>2021</b> , 70, 796-802	19.2	9
544	Long-term Safety and Efficacy of Etrasimod for Ulcerative Colitis: Results from the Open-label Extension of the OASIS Study. <i>Journal of Crohn's and Colitis</i> , <b>2021</b> , 15, 950-959	1.5	8
543	An expert consensus to standardise the assessment of histological disease activity in Crohn's disease clinical trials. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2021</b> , 53, 784-793	6.1	3
542	Innovative approaches to biologic development on the trail of CT-P13: biosimilars, value-added medicines, and biobetters. <i>MAbs</i> , <b>2021</b> , 13, 1868078	6.6	6
541	polymorphisms (P268S, IVS8, G908R, L1007fs, R702W) among Kuwaiti patients with Crohn's disease: A case-control study. <i>Saudi Journal of Gastroenterology</i> , <b>2021</b> , 27, 249-256	3	1
540	The Brain-Gut Axis: Psychological Functioning and Inflammatory Bowel Diseases. <i>Journal of Clinical Medicine</i> , <b>2021</b> , 10,	5.1	5
539	IL-17 Inhibitors and Inflammatory Bowel Diseases: A Postmarketing Study in Vigibase. <i>Clinical Pharmacology and Therapeutics</i> , <b>2021</b> , 110, 159-168	6.1	10
538	Endpoints for Perianal Crohn's Disease Trials: Past, Present and Future. <i>Journal of Crohn's and Colitis</i> , <b>2021</b> , 15, 1387-1398	1.5	3

537	Application of Ultrasound Elastography for Assessing Intestinal Fibrosis in Inflammatory Bowel Disease: Fiction or Reality?. <i>Current Drug Targets</i> , <b>2021</b> , 22, 347-355	3	2
536	Calorie Restriction as a New Treatment of Inflammatory Diseases. <i>Advances in Nutrition</i> , <b>2021</b> , 12, 1558-1570	5	
535	Ulcerative Colitis Narrative Global Survey Findings: The Impact of Living With Ulcerative Colitis-Patients' and Physicians' View. <i>Inflammatory Bowel Diseases</i> , <b>2021</b> , 27, 1747-1755	4.5	2
534	Effectiveness and safety of ustekinumab maintenance therapy in 103 patients with ulcerative colitis: a GETAID cohort study. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2021</b> , 54, 944-951	6.1	2
533	Viral infections in inflammatory bowel disease: Tips and tricks for correct management. <i>World Journal of Gastroenterology</i> , <b>2021</b> , 27, 4276-4297	5.6	2
532	Challenges and Opportunities in IBD Clinical Trial Design. <i>Gastroenterology</i> , <b>2021</b> , 161, 400-404	13.3	1
531	Transmural healing as a therapeutic goal in Crohn's disease: a systematic review. <i>The Lancet Gastroenterology and Hepatology</i> , <b>2021</b> , 6, 659-667	18.8	6
530	International consensus on the prevention of venous and arterial thrombotic events in patients with inflammatory bowel disease. <i>Nature Reviews Gastroenterology and Hepatology</i> , <b>2021</b> , 18, 857-873	24.2	5
529	Gastroenterological safety of IL-17 inhibitors: a systematic literature review. <i>Expert Opinion on Drug Safety</i> , <b>2021</b> , 1-17	4.1	2
528	Telomeres: New players in immune-mediated inflammatory diseases?. <i>Journal of Autoimmunity</i> , <b>2021</b> , 123, 102699	15.5	2
527	Efficacy and Safety of 2 Vedolizumab Intravenous Regimens for Perianal Fistulizing Crohn's Disease: ENTERPRISE Study. <i>Clinical Gastroenterology and Hepatology</i> , <b>2021</b> ,	6.9	7
526	Incidence of and Risk Factors for Colorectal Strictures in Ulcerative Colitis: A Multicenter Study. <i>Clinical Gastroenterology and Hepatology</i> , <b>2021</b> , 19, 1899-1905.e1	6.9	3
525	Histologic Outcomes With Vedolizumab Versus Adalimumab in Ulcerative Colitis: Results From An Efficacy and Safety Study of Vedolizumab Intravenous Compared to Adalimumab Subcutaneous in Participants With Ulcerative Colitis (VARSITY). <i>Gastroenterology</i> , <b>2021</b> , 161, 1156-1167.e3	13.3	2
524	Biosimilar knowledge and viewpoints among Brazilian inflammatory bowel disease patients. <i>Therapeutic Advances in Gastroenterology</i> , <b>2021</b> , 14, 17562848211013249	4.7	0
523	SARS-CoV-2 vaccination in IBD: more pros than cons. <i>Nature Reviews Gastroenterology and Hepatology</i> , <b>2021</b> , 18, 211-213	24.2	16
522	Rediscovering histology: what is new in endoscopy for inflammatory bowel disease?. <i>Therapeutic Advances in Gastroenterology</i> , <b>2021</b> , 14, 17562848211005692	4.7	1
521	Composite outcomes in observational studies of ulcerative colitis: A systematic review and meta-analysis.. <i>United European Gastroenterology Journal</i> , <b>2021</b> ,	5.3	1
520	Sugars and Gastrointestinal Health.. <i>Clinical Gastroenterology and Hepatology</i> , <b>2021</b> ,	6.9	3

519	Confounding and bias in observational studies in inflammatory bowel disease: a meta-epidemiological study. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2021</b> , 53, 712-721	6.1	0
518	Impact of abdominal or pelvic radiotherapy on disease activity in inflammatory bowel disease: a multicentre cohort study from the GETAID. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2021</b> , 53, 400-409	6.1	0
517	Determinants of IBD-related disability: a cross-sectional survey from the GETAID. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2021</b> , 53, 1098-1107	6.1	1
516	Ustekinumab for Perianal Crohn's Disease: The BioLAP Multicenter Study From the GETAID. <i>American Journal of Gastroenterology</i> , <b>2020</b> , 115, 1812-1820	0.7	20
515	Patients with Inflammatory Bowel Disease Are Not at Increased Risk of COVID-19: A Large Multinational Cohort Study. <i>Journal of Clinical Medicine</i> , <b>2020</b> , 9,	5.1	17
514	Incidence and Patterns of COVID-19 Among Inflammatory Bowel Disease Patients From the Nancy and Milan Cohorts. <i>Clinical Gastroenterology and Hepatology</i> , <b>2020</b> , 18, 2134-2135	6.9	71
513	The day after COVID-19 in IBD: how to go back to 'normal'. <i>Nature Reviews Gastroenterology and Hepatology</i> , <b>2020</b> , 17, 441-443	24.2	12
512	Monitoring of inflammatory bowel disease in 2019: A French consensus for clinical practice. <i>Digestive and Liver Disease</i> , <b>2020</b> , 52, 704-720	3.3	2
511	Views of patients with inflammatory bowel disease on the COVID-19 pandemic: a global survey. <i>The Lancet Gastroenterology and Hepatology</i> , <b>2020</b> , 5, 631-632	18.8	43
510	SFED recommendations for IBD endoscopy during COVID-19 pandemic: Italian and French experience. <i>Nature Reviews Gastroenterology and Hepatology</i> , <b>2020</b> , 17, 507-516	24.2	13
509	Targeting the gut layers in Crohn's disease: mucosal or transmural healing?. <i>Expert Review of Gastroenterology and Hepatology</i> , <b>2020</b> , 14, 775-787	4.2	4
508	Motivation to pursue anti-TNF treatment in patients with Crohn's disease - the SPACE motivation study. <i>Digestive and Liver Disease</i> , <b>2020</b> , 52, 995-1001	3.3	0
507	Clinical Research and Trials-A "Nonessential" Victim of the COVID-19 Pandemic?. <i>American Journal of Gastroenterology</i> , <b>2020</b> , 115, 946-947	0.7	2
506	PK, PD, and interactions: the new scenario with JAK inhibitors and S1P receptor modulators, two classes of small molecule drugs, in IBD. <i>Expert Review of Gastroenterology and Hepatology</i> , <b>2020</b> , 14, 797-806	4.2	2
505	Which MRI Score and Technique Should Be Used for Assessing Crohn's Disease Activity?. <i>Journal of Clinical Medicine</i> , <b>2020</b> , 9,	5.1	2
504	ECCO Position Paper: Harmonization of the Approach to Ulcerative Colitis Histopathology. <i>Journal of Crohn's and Colitis</i> , <b>2020</b> , 14, 1503-1511	1.5	34
503	Clinical Trials for Inflammatory Bowel Disease: Global Guidance During the COVID-19 Pandemic. <i>Journal of Crohn's and Colitis</i> , <b>2020</b> , 14, S815-S819	1.5	4
502	Challenges and opportunities for IBD drug development: from early stage to regulatory approval. <i>Gut</i> , <b>2020</b> , 69, 1157-1161	19.2	3

501	Treatment Algorithms for Crohn's Disease. <i>Digestion</i> , <b>2020</b> , 101 Suppl 1, 43-57	3.6	13
500	Emerging therapies for the treatment of ulcerative colitis. <i>Expert Opinion on Emerging Drugs</i> , <b>2020</b> , 1-9	3.7	5
499	Statins and inflammatory bowel disease: Where do we stand?. <i>European Journal of Internal Medicine</i> , <b>2020</b> , 75, 10-14	3.9	4
498	Comparative efficacy and safety of vedolizumab and infliximab in ulcerative colitis after failure of a first subcutaneous anti-TNF agent: a multicentre cohort study. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2020</b> , 51, 852-860	6.1	13
497	Crohn's disease. <i>Nature Reviews Disease Primers</i> , <b>2020</b> , 6, 22	51.1	131
496	Systematic review with meta-analysis: biologics and risk of infection or cancer in elderly patients with inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2020</b> , 51, 820-830	6.1	17
495	Flare-IBD: development and validation of a questionnaire based on patients' messages on an internet forum for early detection of flare in inflammatory bowel disease: study protocol. <i>BMJ Open</i> , <b>2020</b> , 10, e037211	3	1
494	The deficit in folate and vitamin B12 triggers liver macrovesicular steatosis and inflammation in rats with dextran sodium sulfate-induced colitis. <i>Journal of Nutritional Biochemistry</i> , <b>2020</b> , 84, 108415	6.3	8
493	JAK or GUT Selectivity: Tipping the Balance for Efficacy and Safety in Ulcerative Colitis. <i>Journal of Crohn's and Colitis</i> , <b>2020</b> , 14, 1185-1187	1.5	2
492	Positioning ustekinumab in moderate-to-severe ulcerative colitis: new kid on the block. <i>Expert Opinion on Biological Therapy</i> , <b>2020</b> , 20, 421-427	5.4	6
491	Modulation of sphingosine-1-phosphate in ulcerative colitis. <i>Expert Opinion on Biological Therapy</i> , <b>2020</b> , 20, 413-420	5.4	9
490	DOP13 Clinical and endoscopic response to ustekinumab in Crohn's disease: Week 16 interim analysis of the STARDUST trial. <i>Journal of Crohn's and Colitis</i> , <b>2020</b> , 14, S049-S052	1.5	4
489	Vedolizumab for perianal Crohn's disease: a multicentre cohort study in 151 patients. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2020</b> , 51, 719-727	6.1	19
488	Addition of azathioprine to the switch of anti-TNF in patients with IBD in clinical relapse with undetectable anti-TNF trough levels and antidrug antibodies: a prospective randomised trial. <i>Gut</i> , <b>2020</b> , 69, 1206-1212	19.2	45
487	Management of Inflammatory Bowel Diseases: Clinical Perspectives. <i>Clinical Gastroenterology and Hepatology</i> , <b>2020</b> , 18, 1249-1251	6.9	0
486	Review article: faecal calprotectin and histologic remission in ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2020</b> , 51, 689-698	6.1	29
485	Pharmacological Prevention of Postoperative Recurrence in Crohn's Disease. <i>Drugs</i> , <b>2020</b> , 80, 385-399	12.1	4
484	Efficacy and Safety of Upadacitinib in a Randomized Trial of Patients With Crohn's Disease. <i>Gastroenterology</i> , <b>2020</b> , 158, 2123-2138.e8	13.3	75

483	Maintenance of Remission Among Patients With Inflammatory Bowel Disease After Vedolizumab Discontinuation: A Multicentre Cohort Study. <i>Journal of Crohn's and Colitis</i> , <b>2020</b> , 14, 896-903	1.5	4
482	Vedolizumab and etrolizumab for ulcerative colitis: twins or simple cousins?. <i>Expert Opinion on Biological Therapy</i> , <b>2020</b> , 20, 353-361	5.4	3
481	Transmural Histological Scoring Systems in Crohn's Disease: A Systematic Review With Assessment of Methodological Quality and Operating Properties. <i>Journal of Crohn's and Colitis</i> , <b>2020</b> , 14, 743-756	1.5	3
480	Positioning Therapies in Ulcerative Colitis. <i>Clinical Gastroenterology and Hepatology</i> , <b>2020</b> , 18, 1280-1290	6.1	30
479	The Future of Biosimilars: Maximizing Benefits Across Immune-Mediated Inflammatory Diseases. <i>Drugs</i> , <b>2020</b> , 80, 99-113	12.1	32
478	Treatment Adherence in Inflammatory Bowel Disease Patients from Argentina: A Multicenter Study. <i>Gastroenterology Research and Practice</i> , <b>2020</b> , 2020, 4060648	2	3
477	Efficacy of anti-TNF drugs in patients with stricturing Crohn's disease. <i>Expert Review of Gastroenterology and Hepatology</i> , <b>2020</b> , 14, 347-353	4.2	4
476	Diarrhea During COVID-19 Infection: Pathogenesis, Epidemiology, Prevention, and Management. <i>Clinical Gastroenterology and Hepatology</i> , <b>2020</b> , 18, 1663-1672	6.9	285
475	OP01 Higher vs. standard adalimumab maintenance regimens in patients with moderately to severely active ulcerative colitis: Results from the SERENE-UC maintenance study. <i>Journal of Crohn's and Colitis</i> , <b>2020</b> , 14, S001-S001	1.5	11
474	Comparative accuracy of ferritin, transferrin saturation and soluble transferrin receptor for the diagnosis of iron deficiency in inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2020</b> , 51, 1087-1095	6.1	8
473	Surgery for Crohn's disease during pregnancy: A nationwide survey. <i>United European Gastroenterology Journal</i> , <b>2020</b> , 8, 736-740	5.3	1
472	Genomic and molecular alterations in human inflammatory bowel disease-associated colorectal cancer. <i>United European Gastroenterology Journal</i> , <b>2020</b> , 8, 675-684	5.3	6
471	A snapshot of the ongoing clinical research on COVID-19. <i>F1000Research</i> , <b>2020</b> , 9, 373	3.6	4
470	Thiopurines and non-melanoma skin cancer: partners in crime in inflammatory bowel diseases. <i>British Medical Bulletin</i> , <b>2020</b> , 136, 107-117	5.4	1
469	Oral Iron for IBD Patients: Lessons Learned at Time of COVID-19 Pandemic. <i>Journal of Clinical Medicine</i> , <b>2020</b> , 9,	5.1	5
468	Histologically confirmed upper gastrointestinal Crohn's disease: is it rare or are we just not searching hard enough?. <i>Intestinal Research</i> , <b>2020</b> , 18, 210-218	4.1	4
467	DOP79 Dose escalation of upadacitinib in Crohn's disease patients with an inadequate response: Data from the randomised CELEST study. <i>Journal of Crohn's and Colitis</i> , <b>2020</b> , 14, S117-S118	1.5	
466	Patient's profiling for therapeutic management of inflammatory bowel disease: a tailored approach. <i>Expert Review of Gastroenterology and Hepatology</i> , <b>2020</b> , 14, 765-773	4.2	3

465	Impact of HIV Infection on the Course of Inflammatory Bowel Disease and Drug Safety Profile: A Multicenter GETAID Study. <i>Clinical Gastroenterology and Hepatology</i> , <b>2020</b> ,	6.9	1
464	Long-term safety of approved biologics for ulcerative colitis. <i>Expert Opinion on Drug Safety</i> , <b>2020</b> , 19, 807-816	4.1	6
463	Impact of a medical interview on the decision to switch from originator infliximab to its biosimilar in patients with inflammatory bowel disease. <i>Digestive and Liver Disease</i> , <b>2020</b> , 52, 281-288	3.3	8
462	Features of Fecal and Colon Microbiomes Associate With Responses to Biologic Therapies for Inflammatory Bowel Diseases: A Systematic Review. <i>Clinical Gastroenterology and Hepatology</i> , <b>2020</b> , 18, 1054-1069	6.9	18
461	Inflammatory bowel disease: estimates from the global burden of disease 2017 study. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2020</b> , 51, 261-270	6.1	21
460	Safety of Janus Kinase Inhibitors in Patients With Inflammatory Bowel Diseases or Other Immune-mediated Diseases: A Systematic Review and Meta-Analysis. <i>Gastroenterology</i> , <b>2020</b> , 158, 1554-1573.e12	13.3	84
459	Is there a role for therapeutic sphingolipids in inflammatory bowel disease?. <i>Expert Review of Gastroenterology and Hepatology</i> , <b>2020</b> , 14, 47-54	4.2	4
458	Faecal Calprotectin for the Diagnosis of Bowel Inflammation in Patients With Rheumatological Diseases: A Systematic Review. <i>Journal of Crohn's and Colitis</i> , <b>2020</b> , 14, 688-693	1.5	8
457	Mongersen (GED-0301) for Active Crohn's Disease: Results of a Phase 3 Study. <i>American Journal of Gastroenterology</i> , <b>2020</b> , 115, 738-745	0.7	32
456	Histological healing: should it be considered as a new outcome for ulcerative colitis?. <i>Expert Opinion on Biological Therapy</i> , <b>2020</b> , 20, 407-412	5.4	8
455	Real-world evidence of tofacitinib effectiveness and safety in patients with refractory ulcerative colitis. <i>Digestive and Liver Disease</i> , <b>2020</b> , 52, 268-273	3.3	24
454	Efficacy and Safety of Etrasimod in a Phase 2 Randomized Trial of Patients With Ulcerative Colitis. <i>Gastroenterology</i> , <b>2020</b> , 158, 550-561	13.3	63
453	Complete Endoscopic Healing Associated With Better Outcomes Than Partial Endoscopic Healing in Patients With Crohn's Disease. <i>Clinical Gastroenterology and Hepatology</i> , <b>2020</b> , 18, 2256-2261	6.9	10
452	Phase I, II and III Trials in Inflammatory Bowel Diseases: A Practical Guide for the Non-specialist. <i>Journal of Crohn's and Colitis</i> , <b>2020</b> , 14, 710-718	1.5	1
451	Histological Remission in Ulcerative Colitis: Under the Microscope Is the Cure. <i>American Journal of Gastroenterology</i> , <b>2020</b> , 115, 179-189	0.7	23
450	Use of Cross-Sectional Imaging for Tight Monitoring of Inflammatory Bowel Diseases. <i>Clinical Gastroenterology and Hepatology</i> , <b>2020</b> , 18, 1309-1323.e4	6.9	17
449	Evolving primary and secondary endpoints in randomized controlled trials leading to approval of biologics and small molecules in IBD: an historical perspective. <i>Expert Opinion on Biological Therapy</i> , <b>2020</b> , 20, 151-161	5.4	2
448	Multidisciplinary management of the nocebo effect in biosimilar-treated IBD patients: Results of a workshop from the NOCE-BIO consensus group. <i>Digestive and Liver Disease</i> , <b>2020</b> , 52, 138-142	3.3	13

447	Prevalence of endoscopic improvement and remission according to patient-reported outcomes in ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2020</b> , 51, 435-445	6.1	11
446	Evolving therapeutic goals in Crohn's disease management. <i>United European Gastroenterology Journal</i> , <b>2020</b> , 8, 133-139	5.3	5
445	A clinical decision support tool may help to optimise vedolizumab therapy in Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2020</b> , 51, 553-564	6.1	13
444	Defining Endpoints and Biomarkers in Inflammatory Bowel Disease: Moving the Needle Through Clinical Trial Design. <i>Gastroenterology</i> , <b>2020</b> , 159, 2013-2018.e7	13.3	3
443	Herpes Zoster and Vaccination Strategies in Inflammatory Bowel Diseases: A Practical Guide. <i>Clinical Gastroenterology and Hepatology</i> , <b>2020</b> ,	6.9	6
442	Reply. <i>Clinical Gastroenterology and Hepatology</i> , <b>2020</b> , 18, 3055	6.9	1
441	Cobitolimod for moderate-to-severe, left-sided ulcerative colitis (CONDUCT): a phase 2b randomised, double-blind, placebo-controlled, dose-ranging induction trial. <i>The Lancet Gastroenterology and Hepatology</i> , <b>2020</b> , 5, 1063-1075	18.8	11
440	Predictors for short bowel syndrome in Crohn's disease. <i>Digestive and Liver Disease</i> , <b>2020</b> , 52, 1455-1460.3	3.3	1
439	Validation of the Red Flags Index for Early Diagnosis of Crohn's Disease: A Prospective Observational IG-IBD Study Among General Practitioners. <i>Journal of Crohn's and Colitis</i> , <b>2020</b> ,	1.5	5
438	P682 Faecal calprotectin and C-reactive protein levels are associated with long-term clinical and endoscopic outcomes: Analysis of the OASIS open-label extension trial of etrasimod for ulcerative colitis. <i>Journal of Crohn's and Colitis</i> , <b>2020</b> , 14, S555-S556	1.5	
437	Paradoxical gastrointestinal effects of interleukin-17 blockers. <i>Annals of the Rheumatic Diseases</i> , <b>2020</b> , 79, 1132-1138	2.4	49
436	Thiopurines' Metabolites and Drug Toxicity: A Meta-Analysis. <i>Journal of Clinical Medicine</i> , <b>2020</b> , 9,	5.1	6
435	Low Back Pain and Sacroiliitis on Cross-Sectional Abdominal Imaging for Axial Spondyloarthritis Diagnosis in Inflammatory Bowel Diseases. <i>Inflammatory Intestinal Diseases</i> , <b>2020</b> , 5, 124-131	2.5	5
434	New drugs in the pipeline for the treatment of inflammatory bowel diseases: what is coming?. <i>Current Opinion in Pharmacology</i> , <b>2020</b> , 55, 141-150	5.1	6
433	Treat to target or 'treat to clear' in inflammatory bowel diseases: one step further?. <i>Expert Review of Gastroenterology and Hepatology</i> , <b>2020</b> , 14, 807-817	4.2	5
432	Systematic Review on Inflammatory Bowel Disease Patients With Coronavirus Disease 2019: It Is Time to Take Stock. <i>Clinical Gastroenterology and Hepatology</i> , <b>2020</b> , 18, 2689-2700	6.9	38
431	Tools for fecal incontinence assessment: lessons for inflammatory bowel disease trials based on a systematic review. <i>United European Gastroenterology Journal</i> , <b>2020</b> , 8, 886-922	5.3	2
430	Inflammatory Bowel Disease Management During the COVID-19 Outbreak: The Ten Do's and Don'ts from the ECCO-COVID Taskforce. <i>Journal of Crohn's and Colitis</i> , <b>2020</b> , 14, S798-S806	1.5	51

429	Assessment of extraintestinal manifestations in inflammatory bowel diseases: A systematic review and a proposed guide for clinical trials. <i>United European Gastroenterology Journal</i> , <b>2020</b> , 8, 1013-1030	5.3	5
428	Efficacy and Safety of Extended Induction With Tofacitinib for the Treatment of Ulcerative Colitis. <i>Clinical Gastroenterology and Hepatology</i> , <b>2020</b> ,	6.9	5
427	Long-term outcome of Crohn's disease patients with upper gastrointestinal stricture: A GETAID study. <i>Digestive and Liver Disease</i> , <b>2020</b> , 52, 1323-1330	3.3	2
426	Biosimilar switching in inflammatory bowel disease: from evidence to clinical practice. <i>Expert Review of Clinical Immunology</i> , <b>2020</b> , 16, 1019-1028	5.1	5
425	Setting up a Virtual Calprotectin Clinic in Inflammatory Bowel Diseases: Literature Review and Nancy Experience. <i>Journal of Clinical Medicine</i> , <b>2020</b> , 9,	5.1	6
424	Relationship Between Combined Histologic and Endoscopic Endpoints and Efficacy of Ustekinumab Treatment in Patients With Ulcerative Colitis. <i>Gastroenterology</i> , <b>2020</b> , 159, 2052-2064	13.3	17
423	Ulcerative colitis. <i>Nature Reviews Disease Primers</i> , <b>2020</b> , 6, 74	51.1	182
422	Key Strategies to Optimize Outcomes in Mild-to-Moderate Ulcerative Colitis. <i>Journal of Clinical Medicine</i> , <b>2020</b> , 9,	5.1	6
421	Early Intervention in Ulcerative Colitis: Ready for Prime Time?. <i>Journal of Clinical Medicine</i> , <b>2020</b> , 9,	5.1	12
420	Evolving therapeutic goals in ulcerative colitis: towards disease clearance. <i>Nature Reviews Gastroenterology and Hepatology</i> , <b>2020</b> , 17, 1-2	24.2	42
419	Efficacy of Tumor Necrosis Factor Antagonist Treatment in Patients With Refractory Ulcerative Proctitis. <i>Clinical Gastroenterology and Hepatology</i> , <b>2020</b> , 18, 620-627.e1	6.9	7
418	Ulcerative Colitis and Crohn's Disease Have Similar Burden and Goals for Treatment. <i>Clinical Gastroenterology and Hepatology</i> , <b>2020</b> , 18, 14-23	6.9	38
417	Application of Artificial Intelligence to Gastroenterology and Hepatology. <i>Gastroenterology</i> , <b>2020</b> , 158, 76-94.e2	13.3	162
416	Two Cases of Successful Ustekinumab Treatment for Non-infectious Uveitis Associated With Crohn's Disease. <i>Journal of Crohn's and Colitis</i> , <b>2020</b> , 14, 571	1.5	15
415	Modern use of 5-aminosalicylic acid compounds for ulcerative colitis. <i>Expert Opinion on Biological Therapy</i> , <b>2020</b> , 20, 363-378	5.4	22
414	Environmental, Nutritional, and Socioeconomic Determinants of IBD Incidence: A Global Ecological Study. <i>Journal of Crohn's and Colitis</i> , <b>2020</b> , 14, 323-331	1.5	5
413	Effectiveness and safety of ustekinumab induction therapy for 103 patients with ulcerative colitis: a GETAID multicentre real-world cohort study. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2020</b> , 51, 1039-1046	6.1	25
412	Will the Quality of Research Remain the Same During the COVID-19 Pandemic?. <i>Clinical Gastroenterology and Hepatology</i> , <b>2020</b> , 18, 2142	6.9	18

411	Head-to-head trials in inflammatory bowel disease: past, present and future. <i>Nature Reviews Gastroenterology and Hepatology</i> , <b>2020</b> , 17, 365-376	24.2	20
410	Inflammatory Bowel Diseases and COVID-19: The Invisible Enemy. <i>Gastroenterology</i> , <b>2020</b> , 158, 2302-2304	13.3	27
409	Will COVID-19 Infection be Less Severe in Ulcerative Colitis Than in Crohn's Patients, Due to a Lower Rate of Smokers?. <i>Journal of Crohn's and Colitis</i> , <b>2020</b> , 14, 1648	1.5	1
408	Early Intervention With Vedolizumab on Longer Term Surgery Rates in Crohn's Disease: Post Hoc Analysis of the GEMINI Phase 3 and Long-term Safety Programs. <i>Journal of Crohn's and Colitis</i> , <b>2020</b> ,	1.5	3
407	A Global, Prospective, Observational Study Measuring Disease Burden and Suffering in Patients with Ulcerative Colitis Using the Pictorial Representation of Illness and Self-Measure Tool. <i>Journal of Crohn's and Colitis</i> , <b>2020</b> ,	1.5	5
406	Effectiveness And Safety Of Ustekinumab Intensification At 90 Mg Every Four Weeks In Crohn's Disease: A Multicenter Study. <i>Journal of Crohn's and Colitis</i> , <b>2020</b> ,	1.5	14
405	Mucosal Healing in Crohn's Disease and Ulcerative Colitis.. <i>Gastroenterology and Hepatology</i> , <b>2020</b> , 16, 206-208	0.7	
404	Sa1812 Endoscopic and Deep Remission At 1 Year Prevents Disease Progression in Early Crohn's Disease: Long-Term Data from Calm. <i>Gastroenterology</i> , <b>2019</b> , 156, S-411	13.3	3
403	Approaches to Integrating Biomarkers Into Clinical Trials and Care Pathways as Targets for the Treatment of Inflammatory Bowel Diseases. <i>Gastroenterology</i> , <b>2019</b> , 157, 1032-1043.e1	13.3	31
402	Interleukin-23 Blockers: Born to be First-line Biologic Agents in Inflammatory Bowel Disease?. <i>Current Pharmaceutical Design</i> , <b>2019</b> , 25, 25-31	3.3	5
401	Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis. <i>New England Journal of Medicine</i> , <b>2019</b> , 381, 1215-1226	59.2	240
400	Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis. <i>New England Journal of Medicine</i> , <b>2019</b> , 381, 1201-1214	59.2	354
399	OP37 Efficacy and safety of ustekinumab as maintenance therapy in ulcerative colitis: Week 44 results from UNIFI. <i>Journal of Crohn's and Colitis</i> , <b>2019</b> , 13, S025-S026	1.5	12
398	DOP71 Effects of ustekinumab induction therapy on endoscopic and histological healing in the UNIFI Phase 3 study in ulcerative colitis. <i>Journal of Crohn's and Colitis</i> , <b>2019</b> , 13, S073-S073	1.5	2
397	Psychological Characteristics of Inflammatory Bowel Disease Patients: A Comparison Between Active and Nonactive Patients. <i>Inflammatory Bowel Diseases</i> , <b>2019</b> , 25, 1399-1407	4.5	11
396	Vedolizumab Trough Levels and Histological Healing During Maintenance Therapy in Ulcerative Colitis. <i>Journal of Crohn's and Colitis</i> , <b>2019</b> , 13, 970-975	1.5	26
395	Personalised medicine in inflammatory bowel diseases: a patient survey. <i>Scandinavian Journal of Gastroenterology</i> , <b>2019</b> , 54, 135	2.4	1
394	JAK selectivity for inflammatory bowel disease treatment: does it clinically matter?. <i>Gut</i> , <b>2019</b> , 68, 1893-1899	13.2	55

393	Activation of the VEGFC/VEGFR3 Pathway Induces Tumor Immune Escape in Colorectal Cancer. <i>Cancer Research</i> , <b>2019</b> , 79, 4196-4210	10.1	34
392	Cost-of-illness of inflammatory bowel disease patients treated with anti-tumour necrosis factor: A French large single-centre experience. <i>United European Gastroenterology Journal</i> , <b>2019</b> , 7, 908-913	5.3	3
391	Three-year effectiveness and safety of vedolizumab therapy for inflammatory bowel disease: a prospective multi-centre cohort study. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2019</b> , 50, 40-53	6.1	29
390	P312 Efficacy in biologic failure and non-biologic-failure populations in a Phase 3 study of ustekinumab in moderate-to-severe ulcerative colitis: UNIFI. <i>Journal of Crohn's and Colitis</i> , <b>2019</b> , 13, S256-S257	1.5	1
389	Tofacitinib in the treatment of ulcerative colitis: efficacy and safety from clinical trials to real-world experience. <i>Therapeutic Advances in Gastroenterology</i> , <b>2019</b> , 12, 1756284819848631	4.7	33
388	Effectiveness of Infliximab Biosimilar in Crohn's Disease: A Dime, A Dozen. <i>Gastroenterology</i> , <b>2019</b> , 156, 2349-2351	13.3	1
387	Vedolizumab Treatment in Extra-Intestinal Manifestations in Inflammatory Bowel Disease: A Systematic Review. <i>Journal of Crohn's and Colitis</i> , <b>2019</b> , 13, 1569-1577	1.5	19
386	Detection and management of early stage inflammatory bowel disease: an update for clinicians. <i>Expert Review of Gastroenterology and Hepatology</i> , <b>2019</b> , 13, 547-555	4.2	4
385	Vedolizumab Therapy is Ineffective for Primary Sclerosing Cholangitis in Patients With Inflammatory Bowel Disease: A GETAID Multicentre Cohort Study. <i>Journal of Crohn's and Colitis</i> , <b>2019</b> , 13, 1239-1247	1.5	18
384	Psychological Functioning of Patients With Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , <b>2019</b> , 25, e112	4.5	0
383	Vedolizumab for the treatment of inflammatory bowel diseases: from symptomatic control to mucosal healing. <i>Immunotherapy</i> , <b>2019</b> , 11, 565-575	3.8	2
382	Lymphatic endothelium contributes to colorectal cancer growth via the soluble matrisome component GDF11. <i>International Journal of Cancer</i> , <b>2019</b> , 145, 1913-1920	7.5	11
381	Impact of inflammatory bowel diseases on working life: A French nationwide survey. <i>Digestive and Liver Disease</i> , <b>2019</b> , 51, 961-966	3.3	10
380	The Selective Sphingosine 1-Phosphate Receptor Modulator Etrasimod Regulates Lymphocyte Trafficking and Alleviates Experimental Colitis. <i>Journal of Pharmacology and Experimental Therapeutics</i> , <b>2019</b> , 369, 311-317	4.7	20
379	P400 Discordance in patient and physician perspectives and priorities in communication and management of ulcerative colitis: results of the European ulcerative colitis narrative survey. <i>Journal of Crohn's and Colitis</i> , <b>2019</b> , 13, S308-S308	1.5	
378	Consensus report: clinical recommendations for the prevention and management of the nocebo effect in biosimilar-treated IBD patients. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2019</b> , 49, 1181-1187	6.1	31
377	Efficacy, Tolerability, and Safety of Low-Volume Bowel Preparations for Patients with Inflammatory Bowel Diseases: The French Multicentre CLEAN Study. <i>Journal of Crohn's and Colitis</i> , <b>2019</b> , 13, 1121-1130	1.5	6
376	A Simplified Definition of Histologic Improvement in Ulcerative Colitis and its Association With Disease Outcomes up to 30 Weeks from Initiation of Therapy: Post Hoc Analysis of Three Clinical Trials. <i>Journal of Crohn's and Colitis</i> , <b>2019</b> , 13, 1025-1035	1.5	7

375	Unmet Medical Needs in Ulcerative Colitis: An Expert Group Consensus. <i>Digestive Diseases</i> , <b>2019</b> , 37, 266-283	3.2	29
374	Responsiveness of histological disease activity indices in ulcerative colitis: a post hoc analysis using data from the TOUCHSTONE randomised controlled trial. <i>Gut</i> , <b>2019</b> , 68, 1162-1168	19.2	27
373	Combination Therapy With Vedolizumab and Tofacitinib in a Patient With Ulcerative Colitis and Spondyloarthritis. <i>Clinical Gastroenterology and Hepatology</i> , <b>2019</b> , 17, 794-796	6.9	17
372	Anti-TNF biosimilars in Crohn's Disease: a patient-centric interdisciplinary approach. <i>Expert Review of Gastroenterology and Hepatology</i> , <b>2019</b> , 13, 731-738	4.2	10
371	A Treat-to-Target Update in Ulcerative Colitis: A Systematic Review. <i>American Journal of Gastroenterology</i> , <b>2019</b> , 114, 874-883	0.7	90
370	mTOR-Dependent Stimulation of Orchestrates Immune Cell Trafficking through Lymphatic Endothelium in Patients with Crohn's Disease. <i>Cells</i> , <b>2019</b> , 8,	7.9	6
369	A multicentre prospective cohort study assessing the effectiveness of budesonide MMX (Cortiment) for active, mild-to-moderate ulcerative colitis. <i>United European Gastroenterology Journal</i> , <b>2019</b> , 7, 1171-1182	5.3	5
368	Environmental Risk Factors for Inflammatory Bowel Diseases: An Umbrella Review of Meta-analyses. <i>Gastroenterology</i> , <b>2019</b> , 157, 647-659.e4	13.3	155
367	Comparative assessment of budesonide-MMX and mesalamine in active, mild-to-moderate ulcerative colitis: A systematic review and network meta-analysis. <i>British Journal of Clinical Pharmacology</i> , <b>2019</b> , 85, 2244-2254	3.8	5
366	Comorbidities in inflammatory bowel disease: a call for action. <i>The Lancet Gastroenterology and Hepatology</i> , <b>2019</b> , 4, 643-654	18.8	43
365	Noninvasive Multimodal Methods to Differentiate Inflamed vs Fibrotic Strictures in Patients With Crohn's Disease. <i>Clinical Gastroenterology and Hepatology</i> , <b>2019</b> , 17, 2397-2415	6.9	22
364	Challenges in the Pathophysiology, Diagnosis and Management of Intestinal Fibrosis in Inflammatory Bowel Disease. <i>Gastroenterology</i> , <b>2019</b> ,	13.3	17
363	P136 Association between histological indices and ulcerative colitis activity measures among patients in the HICKORY (etrolizumab) open-label induction cohort. <i>Journal of Crohn's and Colitis</i> , <b>2019</b> , 13, S157-S158	1.5	
362	Efficacy, Safety and Immunogenicity of Biosimilars in Inflammatory Bowel Diseases: A Systematic Review. <i>Current Medicinal Chemistry</i> , <b>2019</b> , 26, 270-279	4.3	16
361	Biosimilars for the Management of Inflammatory Bowel Diseases: Economic Considerations. <i>Current Medicinal Chemistry</i> , <b>2019</b> , 26, 259-269	4.3	25
360	Anti-adhesion Molecules in IBD: Does Gut Selectivity Really Make the Difference?. <i>Current Pharmaceutical Design</i> , <b>2019</b> , 25, 19-24	3.3	1
359	Anti-fibrotic Drugs for Crohn's Disease: Ready for Prime Time?. <i>Current Pharmaceutical Design</i> , <b>2019</b> , 25, 47-56	3.3	2
358	Biosimilars of Adalimumab in Inflammatory Bowel Disease: Are we Ready for that?. <i>Current Pharmaceutical Design</i> , <b>2019</b> , 25, 7-12	3.3	6

357 Disease Modification in Crohn's Disease **2019**, 23-29

356	Efficacy and Safety of Ustekinumab as Maintenance Therapy in Ulcerative Colitis: Week 44 Results from UNIFI <b>2019</b> , 57,		2
355	Effects of Ustekinumab Induction Therapy on Endoscopic and Histologic Healing in the UNIFI Phase 3 Study in Ulcerative Colitis <b>2019</b> , 57,		1
354	Efficacy of biological drugs in short-duration versus long-duration inflammatory bowel disease: a protocol for a systematic review and an individual-patient level meta-analysis of randomised controlled trials. <i>BMJ Open</i> , <b>2019</b> , 9, e024222	3	4
353	Time to include patients with ulcerative proctitis in clinical trials. <i>The Lancet Gastroenterology and Hepatology</i> , <b>2019</b> , 4, 900-902	18.8	2
352	Efficacy and safety of biologic agents and tofacitinib in moderate-to-severe ulcerative colitis: A systematic overview of meta-analyses. <i>United European Gastroenterology Journal</i> , <b>2019</b> , 7, 1285-1303	5.3	14
351	Changes in inflammatory bowel disease patients' perspectives on biosimilars: A follow-up survey. <i>United European Gastroenterology Journal</i> , <b>2019</b> , 7, 1345-1352	5.3	15
350	P380 A prospective multi-centre observational cohort study assessing the effectiveness of Budesonide MMX <sup>®</sup> for mild-to-moderate ulcerative colitis. <i>Journal of Crohn's and Colitis</i> , <b>2019</b> , 13, S296-S297	1.5	97
349	Loss of Response to Vedolizumab and Ability of Dose Intensification to Restore Response in Patients With Crohn's Disease or Ulcerative Colitis: A Systematic Review and Meta-analysis. <i>Clinical Gastroenterology and Hepatology</i> , <b>2019</b> , 17, 838-846.e2	6.9	62
348	Effectiveness of golimumab in ulcerative colitis: A review of the real world evidence. <i>Digestive and Liver Disease</i> , <b>2019</b> , 51, 327-334	3.3	14
347	Bispecific antibodies: The next generation of targeted inflammatory bowel disease therapies. <i>Autoimmunity Reviews</i> , <b>2019</b> , 18, 123-128	13.6	18
346	Biosimilars of adalimumab: the upcoming challenge in IBD. <i>Expert Opinion on Biological Therapy</i> , <b>2019</b> , 19, 1023-1030	5.4	13
345	Dose de-escalation to adalimumab 40 mg every three weeks in patients with inflammatory bowel disease-A multicenter, retrospective, observational study. <i>Digestive and Liver Disease</i> , <b>2019</b> , 51, 236-241	3.3	10
344	Vaccination for influenza and pneumococcus in patients with gastrointestinal cancer or inflammatory bowel disease: A prospective cohort study of methods for improving coverage. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2019</b> , 49, 84-90	6.1	8
343	Big data in IBD: a look into the future. <i>Nature Reviews Gastroenterology and Hepatology</i> , <b>2019</b> , 16, 312-324	14.2	58
342	Treatment Persistence of Infliximab Versus Adalimumab in Ulcerative Colitis: A 16-Year Single-Center Experience. <i>Inflammatory Bowel Diseases</i> , <b>2019</b> , 25, 945-954	4.5	11
341	Comparison of the EMA and FDA Guidelines on Ulcerative Colitis Drug Development. <i>Clinical Gastroenterology and Hepatology</i> , <b>2019</b> , 17, 1673-1679.e1	6.9	13
340	Cost savings using a test-based de-escalation strategy for patients with Crohn's disease in remission on optimized infliximab: A discrete event model study. <i>Digestive and Liver Disease</i> , <b>2019</b> , 51, 112-119	3.3	11

339	Metagenomic analysis of intestinal mucosa revealed a specific eukaryotic gut virome signature in early-diagnosed inflammatory bowel disease. <i>Gut Microbes</i> , <b>2019</b> , 10, 149-158	8.8	36
338	Early changes in the pharmacokinetic profile of vedolizumab-treated patients with IBD may predict response after dose optimisation. <i>Gut</i> , <b>2019</b> , 68, 178-179	19.2	7
337	P671 Calprotectin does not add accuracy to PRO2 for prediction of continuous clinical response in moderate-to-severe ulcerative colitis patients treated with golimumab. <i>Journal of Crohn's and Colitis</i> , <b>2018</b> , 12, S450-S450	1.5	
336	Positioning Tofacitinib in the Treatment Algorithm of Moderate to Severe Ulcerative Colitis. <i>Inflammatory Bowel Diseases</i> , <b>2018</b> , 24, 2106-2112	4.5	11
335	Effectiveness and safety of anti-TNF therapy for inflammatory bowel disease in liver transplant recipients for primary sclerosing cholangitis: A nationwide case series. <i>Digestive and Liver Disease</i> , <b>2018</b> , 50, 668-674	3.3	13
334	Pneumococcal and influenza vaccine uptake in adults with inflammatory bowel disease in France: Results from a web-based study. <i>Digestive and Liver Disease</i> , <b>2018</b> , 50, 563-567	3.3	13
333	Increasing Infliximab Dose Based on Symptoms, Biomarkers, and Serum Drug Concentrations Does Not Increase Clinical, Endoscopic, and Corticosteroid-Free Remission in Patients With Active Luminal Crohn's Disease. <i>Gastroenterology</i> , <b>2018</b> , 154, 1343-1351.e1	13.3	164
332	Telehealth in Inflammatory Bowel Disease: Every Patient May Need a Coach!. <i>Gastroenterology</i> , <b>2018</b> , 154, 1196-1198	13.3	2
331	Early vedolizumab trough levels predict mucosal healing in inflammatory bowel disease: a multicentre prospective observational study. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2018</b> , 47, 906-912	6.1	67
330	P573 Safety and immune modulatory properties of etrasimod (APD334), a next-generation oral, selective sphingosine 1-phosphate receptor (S1PR) modulator, in healthy volunteers. <i>Journal of Crohn's and Colitis</i> , <b>2018</b> , 12, S397-S397	1.5	4
329	Vedolizumab for the treatment of Crohn's disease. <i>Expert Review of Clinical Immunology</i> , <b>2018</b> , 14, 179-189	3.9	6
328	Physicians' perspective on the clinical meaningfulness of inflammatory bowel disease trial results: an International Organization for the Study of Inflammatory Bowel Disease (IOIBD) survey. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2018</b> , 47, 773-783	6.1	4
327	High Risk of Anal and Rectal Cancer in Patients With Anal and/or Perianal Crohn's Disease. <i>Clinical Gastroenterology and Hepatology</i> , <b>2018</b> , 16, 892-899.e2	6.9	45
326	Impact of vedolizumab therapy on extra-intestinal manifestations in patients with inflammatory bowel disease: a multicentre cohort study nested in the OBSERV-IBD cohort. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2018</b> , 47, 485-493	6.1	61
325	Long-term efficacy and safety of ustekinumab in 122 refractory Crohn's disease patients: a multicentre experience. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2018</b> , 47, 588-595	6.1	51
324	Thiopurines in Inflammatory Bowel Disease: New Findings and Perspectives. <i>Journal of Crohn's and Colitis</i> , <b>2018</b> , 12, 610-620	1.5	37
323	It is Time to Revise the STRIDE Guidelines Determining Therapeutic Goals for Treat-to-Target in Inflammatory Bowel Disease. <i>Journal of Crohn's and Colitis</i> , <b>2018</b> , 12, 509	1.5	24
322	Diffusion-weighted MRI in inflammatory bowel disease. <i>The Lancet Gastroenterology and Hepatology</i> , <b>2018</b> , 3, 433-443	18.8	13

321	Is the Pharmacokinetic Profile of a First Anti-TNF Predictive of the Clinical Outcome and Pharmacokinetics of a Second Anti-TNF?. <i>Inflammatory Bowel Diseases</i> , <b>2018</b> , 24, 2078-2085	4.5	18
320	Infliximab biosimilar CT-P13 for inflammatory bowel disease. <i>The Lancet Gastroenterology and Hepatology</i> , <b>2018</b> , 3, 373-375	18.8	5
319	Heterogeneity in Definitions of Efficacy and Safety Endpoints for Clinical Trials of Crohn's Disease: A Systematic Review. <i>Clinical Gastroenterology and Hepatology</i> , <b>2018</b> , 16, 1407-1419.e22	6.9	29
318	Identification of Endpoints for Development of Antifibrosis Drugs for Treatment of Crohn's Disease. <i>Gastroenterology</i> , <b>2018</b> , 155, 76-87	13.3	29
317	Development of an index to define overall disease severity in IBD. <i>Gut</i> , <b>2018</b> , 67, 244-254	19.2	73
316	Efficacy of adalimumab in patients with Crohn's disease and symptomatic small bowel stricture: a multicentre, prospective, observational cohort (CREOLE) study. <i>Gut</i> , <b>2018</b> , 67, 53-60	19.2	126
315	Natural History of Adult Ulcerative Colitis in Population-based Cohorts: A Systematic Review. <i>Clinical Gastroenterology and Hepatology</i> , <b>2018</b> , 16, 343-356.e3	6.9	161
314	Comparative safety of systemic and low-bioavailability steroids in inflammatory bowel disease: Systematic review and network meta-analysis. <i>British Journal of Clinical Pharmacology</i> , <b>2018</b> , 84, 239-251 <sup>3.8</sup>	13.8	24
313	Systematic review and meta-analysis: assessment of factors affecting disability in inflammatory bowel disease and the reliability of the inflammatory bowel disease disability index. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2018</b> , 47, 6-15	6.1	29
312	Prolonged azathioprine treatment reduces the need for surgery in early Crohn's disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2018</b> , 33, 664-670	4	7
311	Heterogeneity in Definitions of Endpoints for Clinical Trials of Ulcerative Colitis: A Systematic Review for Development of a Core Outcome Set. <i>Clinical Gastroenterology and Hepatology</i> , <b>2018</b> , 16, 637-647.e13	6.9	27
310	Systematic screening for primary sclerosing cholangitis with magnetic resonance cholangiography in inflammatory bowel disease. <i>Digestive and Liver Disease</i> , <b>2018</b> , 50, 1012-1018	3.3	11
309	Review article: treating-to-target for inflammatory bowel disease-associated anaemia. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2018</b> , 48, 610-617	6.1	19
308	Accuracy of Diffusion-weighted Magnetic Resonance Imaging in Detecting Mucosal Healing and Treatment Response, and in Predicting Surgery, in Crohn's Disease. <i>Journal of Crohn's and Colitis</i> , <b>2018</b> , 12, 1180-1190	1.5	16
307	Comparative Accuracy of Bowel Ultrasound Versus Magnetic Resonance Enterography in Combination With Colonoscopy in Assessing Crohn's Disease and Guiding Clinical Decision-making. <i>Journal of Crohn's and Colitis</i> , <b>2018</b> , 12, 1280-1287	1.5	39
306	Should we use anti-tumor necrosis factor agents or vedolizumab as first-line biological therapy in ulcerative colitis?. <i>Baillieres Best Practice and Research in Clinical Gastroenterology</i> , <b>2018</b> , 32-33, 17-25	2.5	7
305	Post-operative complications in elderly onset inflammatory bowel disease: a population-based study. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2018</b> , 47, 1652-1660	6.1	5
304	The nocebo effect: a clinical challenge in the era of biosimilars. <i>Expert Review of Clinical Immunology</i> , <b>2018</b> , 14, 739-749	5.1	49

303	Biologic Therapies in Ulcerative Colitis: Primi Inter Pares?. <i>Current Drug Targets</i> , <b>2018</b> , 19, 748-756	3	2
302	Accuracy of Humanitas Ultrasound Criteria in Assessing Disease Activity and Severity in Ulcerative Colitis: A Prospective Study. <i>Journal of Crohn's and Colitis</i> , <b>2018</b> , 12, 1385-1391	1.5	40
301	DOP001 Effectiveness and safety of vedolizumab in anti-TNF naïve patients with inflammatory bowel disease: a multicentre retrospective European Crohn's and Colitis Organisation study. <i>Journal of Crohn's and Colitis</i> , <b>2018</b> , 12, S029-S030	1.5	2
300	Systematic review with meta-analysis: real-world effectiveness and safety of vedolizumab in patients with inflammatory bowel disease. <i>Journal of Gastroenterology</i> , <b>2018</b> , 53, 1048-1064	6.9	67
299	Safety of biological therapies in ulcerative colitis: An umbrella review of meta-analyses. <i>Baillieres's Best Practice and Research in Clinical Gastroenterology</i> , <b>2018</b> , 32-33, 43-47	2.5	20
298	Systematic review with network meta-analysis: comparative assessment of tofacitinib and biological therapies for moderate-to-severe ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2018</b> , 47, 454-465	6.1	87
297	Consensus recommendations for patient-centered therapy in mild-to-moderate ulcerative colitis: the i Support Therapy-Access to Rapid Treatment (iSTART) approach. <i>Intestinal Research</i> , <b>2018</b> , 16, 522-528	4.1	11
296	Evolving Treatment Algorithms in Crohn's Disease. <i>Current Drug Targets</i> , <b>2018</b> , 19, 782-790	3	2
295	Anti-TNF therapy for genital fistulas in female patients with Crohn's disease: a nationwide study from the Groupe d'Etude Thérapeutique des Affections Inflammatoires du tube Digestif (GETAID). <i>Alimentary Pharmacology and Therapeutics</i> , <b>2018</b> , 48, 831-838	6.1	2
294	Effectiveness and Safety of Vedolizumab in Anti-TNF-Naïve Patients With Inflammatory Bowel Disease-A Multicenter Retrospective European Study. <i>Inflammatory Bowel Diseases</i> , <b>2018</b> , 24, 2442-2451	4.5	42
293	Colorectal cancer prevention in patients with ulcerative colitis. <i>Baillieres's Best Practice and Research in Clinical Gastroenterology</i> , <b>2018</b> , 32-33, 103-109	2.5	35
292	Quality of Care in Ulcerative Colitis: A Modified Delphi Panel Approach. <i>Digestive Diseases</i> , <b>2018</b> , 36, 346-353	3.5	3
291	Clinical efficacy of the Toll-like receptor 9 agonist cobitolimod using patient-reported-outcomes defined clinical endpoints in patients with ulcerative colitis. <i>Digestive and Liver Disease</i> , <b>2018</b> , 50, 1019-1029	3.3	12
290	Meta-Analysis of the Association Between Anti-Tumour Necrosis Factor Use and Lymphoma Risk in Patients With Inflammatory Bowel Disease: Methodological Considerations. <i>Journal of Crohn's and Colitis</i> , <b>2018</b> , 12, 1257-1258	1.5	1
289	Thérapies complémentaires et alternatives: quelle place dans les maladies inflammatoires chroniques intestinales?. <i>HEGEL - Hépatogastro-Entérologie Libérale</i> , <b>2018</b> , N° 3, 190-198	0.1	
288	Validation of the Inflammatory Bowel Disease Disability Index in a population-based cohort. <i>Gut</i> , <b>2017</b> , 66, 588-596	19.2	82
287	Development and validation of the Nancy histological index for UC. <i>Gut</i> , <b>2017</b> , 66, 43-49	19.2	196
286	25-OH vitamin D level has no impact on the efficacy of antiviral therapy in naïve genotype 1 HCV-infected patients. <i>United European Gastroenterology Journal</i> , <b>2017</b> , 5, 69-75	5.3	8

285	Systematic Review of Tumor Necrosis Factor Antagonists in Extraintestinal Manifestations in Inflammatory Bowel Disease. <i>Clinical Gastroenterology and Hepatology</i> , <b>2017</b> , 15, 25-36.e27	6.9	75
284	Azathioprine for refractory ulcerative proctitis: A retrospective multicenter study. <i>Digestive and Liver Disease</i> , <b>2017</b> , 49, 280-285	3.3	10
283	Defining endoscopic response and remission in ulcerative colitis clinical trials: an international consensus. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2017</b> , 45, 801-813	6.1	64
282	Next generation of small molecules in inflammatory bowel disease. <i>Gut</i> , <b>2017</b> , 66, 199-209	19.2	78
281	Primetime for e-health in IBD?. <i>Nature Reviews Gastroenterology and Hepatology</i> , <b>2017</b> , 14, 133-134	24.2	9
280	IBD immunopathogenesis: A comprehensive review of inflammatory molecules. <i>Autoimmunity Reviews</i> , <b>2017</b> , 16, 416-426	13.6	149
279	Systematic review with meta-analysis: use of 5-aminosalicylates and risk of colorectal neoplasia in patients with inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2017</b> , 45, 1179-1192	6.1	54
278	Modulation of sphingosine-1-phosphate in inflammatory bowel disease. <i>Autoimmunity Reviews</i> , <b>2017</b> , 16, 495-503	13.6	74
277	Review article: moving towards common therapeutic goals in Crohn's disease and rheumatoid arthritis. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2017</b> , 45, 1058-1072	6.1	35
276	JAK inhibition in inflammatory bowel disease. <i>Expert Review of Clinical Immunology</i> , <b>2017</b> , 13, 693-703	5.1	55
275	Compliance with the faecal calprotectin test in patients with inflammatory bowel disease. <i>United European Gastroenterology Journal</i> , <b>2017</b> , 5, 702-707	5.3	21
274	Genetic Factors Interact With Tobacco Smoke to Modify Risk for Inflammatory Bowel Disease in Humans and Mice. <i>Gastroenterology</i> , <b>2017</b> , 153, 550-565	13.3	43
273	Surgical rates in the era of biological therapy: up, down or unchanged?. <i>Current Opinion in Gastroenterology</i> , <b>2017</b> , 33, 246-253	3	45
272	Cost-utility of biological treatment sequences for luminal Crohn's disease in Europe. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , <b>2017</b> , 17, 597-606	2.2	18
271	Azathioprine dose reduction in inflammatory bowel disease patients on combination therapy: an open-label, prospective and randomised clinical trial. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2017</b> , 46, 142-149	6.1	79
270	Crohn's disease. <i>Lancet, The</i> , <b>2017</b> , 389, 1741-1755	40	829
269	Ulcerative colitis. <i>Lancet, The</i> , <b>2017</b> , 389, 1756-1770	40	1146
268	No Excess Cancer Recurrence After Immunosuppressive Drugs in a Meta-analysis of Cohorts of Patients With Immune-mediated Diseases: A 'Mirage' Related to 'Propensity' Bias?. <i>Gastroenterology</i> , <b>2017</b> , 152, 304-306	13.3	2

267	Positioning Ustekinumab in Crohn's Disease: From Clinical Evidence to Clinical Practice. <i>Journal of Crohn's and Colitis</i> , <b>2017</b> , 11, 1258-1266	1.5	13
266	One-year effectiveness and safety of vedolizumab therapy for inflammatory bowel disease: a prospective multicentre cohort study. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2017</b> , 46, 310-321	6.1	85
265	Vaccination recommendations for the adult immunosuppressed patient: A systematic review and comprehensive field synopsis. <i>Journal of Autoimmunity</i> , <b>2017</b> , 80, 10-27	15.5	78
264	Systematic review with meta-analysis: comparative efficacy of biologics for induction and maintenance of mucosal healing in Crohn's disease and ulcerative colitis controlled trials. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2017</b> , 45, 1291-1302	6.1	160
263	Treatment Persistence for Infliximab Versus Adalimumab in Crohn's Disease: A 14-Year Single-Center Experience. <i>Inflammatory Bowel Diseases</i> , <b>2017</b> , 23, 976-985	4.5	24
262	French national consensus clinical guidelines for the management of Crohn's disease. <i>Digestive and Liver Disease</i> , <b>2017</b> , 49, 368-377	3.3	13
261	ECCO Position Statement on the Use of Biosimilars for Inflammatory Bowel Disease-An Update. <i>Journal of Crohn's and Colitis</i> , <b>2017</b> , 11, 26-34	1.5	148
260	The effects of aminosalicylates or thiopurines on the risk of colorectal cancer in inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2017</b> , 45, 533-541	6.1	26
259	Distinct Thresholds of Infliximab Trough Level Are Associated with Different Therapeutic Outcomes in Patients with Inflammatory Bowel Disease: A Prospective Observational Study. <i>Inflammatory Bowel Diseases</i> , <b>2017</b> , 23, 2048-2053	4.5	29
258	Microbiota in digestive cancers: our new partner?. <i>Carcinogenesis</i> , <b>2017</b> , 38, 1157-1166	4.6	9
257	Previous Exposure to Multiple Anti-TNF Is Associated with Decreased Efficiency in Preventing Postoperative Crohn's Disease Recurrence. <i>Journal of Crohn's and Colitis</i> , <b>2017</b> , 11, 281-288	1.5	14
256	Head-to-head Comparative Studies: Challenges and Opportunities?. <i>Journal of Crohn's and Colitis</i> , <b>2017</b> , 11, S567-S575	1.5	5
255	Prevalence of Bowel Damage Assessed by Cross-Sectional Imaging in Early Crohn's Disease and its Impact on Disease Outcome. <i>Journal of Crohn's and Colitis</i> , <b>2017</b> , 11, 274-280	1.5	29
254	Incidence and Phenotype at Diagnosis of Very-early-onset Compared with Later-onset Paediatric Inflammatory Bowel Disease: A Population-based Study [1988-2011]. <i>Journal of Crohn's and Colitis</i> , <b>2017</b> , 11, 519-526	1.5	44
253	Adherence to infliximab therapy in inflammatory bowel disease patients in a real-life setting. <i>Journal of Digestive Diseases</i> , <b>2017</b> , 18, 566-573	3.3	8
252	E-health in inflammatory bowel diseases: More challenges than opportunities?. <i>Digestive and Liver Disease</i> , <b>2017</b> , 49, 1320-1326	3.3	16
251	Management of patients with inflammatory bowel disease and spondyloarthritis. <i>Expert Review of Clinical Pharmacology</i> , <b>2017</b> , 10, 1363-1374	3.8	11
250	Ulcerative proctitis is a frequent location of paediatric-onset UC and not a minor disease: a population-based study. <i>Gut</i> , <b>2017</b> , 66, 1912-1917	19.2	16

249	Early intervention in Crohn's disease: towards disease modification trials. <i>Gut</i> , <b>2017</b> , 66, 2179-2187	19.2	60
248	Comparative Acceptability and Perceived Clinical Utility of Monitoring Tools: A Nationwide Survey of Patients with Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , <b>2017</b> , 23, 1425-1433	4.5	82
247	Value of cross-sectional imaging in assessing active Crohn's disease before stoma reversal. <i>Digestive and Liver Disease</i> , <b>2017</b> , 49, 864-871	3.3	2
246	Infection Risk With Biologic Therapy in Patients With Inflammatory Bowel Disease. <i>Clinical Pharmacology and Therapeutics</i> , <b>2017</b> , 102, 633-641	6.1	25
245	Development of the IBD Disk: A Visual Self-administered Tool for Assessing Disability in Inflammatory Bowel Diseases. <i>Inflammatory Bowel Diseases</i> , <b>2017</b> , 23, 333-340	4.5	42
244	Tofacitinib Is the Right OCTAVE for Ulcerative Colitis. <i>Gastroenterology</i> , <b>2017</b> , 153, 862-864	13.3	6
243	DOP025 Efficacy of vedolizumab on extraintestinal manifestation in patients with inflammatory bowel disease: a post-hoc analysis of the OBSERV-IBD cohort from the GETAID. <i>Journal of Crohn's and Colitis</i> , <b>2017</b> , 11, S42-S42	1.5	8
242	MFSD2A Promotes Endothelial Generation of Inflammation-Resolving Lipid Mediators and Reduces Colitis in Mice. <i>Gastroenterology</i> , <b>2017</b> , 153, 1363-1377.e6	13.3	34
241	Letter: addition of methotrexate neither restores clinical response nor improves the pharmacokinetic profile of vedolizumab-treated patients. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2017</b> , 46, 1019-1020	6.1	12
240	Preventing disability in inflammatory bowel disease. <i>Therapeutic Advances in Gastroenterology</i> , <b>2017</b> , 10, 865-876	4.7	18
239	Filgotinib in Crohn's Disease: JAK Is Back. <i>Gastroenterology</i> , <b>2017</b> , 153, 603-605	13.3	12
238	Novel therapeutic targets for inflammatory bowel disease. <i>Journal of Autoimmunity</i> , <b>2017</b> , 85, 103-116	15.5	66
237	IBD: To switch or not to switch: that is the biosimilar question. <i>Nature Reviews Gastroenterology and Hepatology</i> , <b>2017</b> , 14, 508-509	24.2	8
236	Implementing the Concept of Continuous Clinical Response Into Clinical Practice for Ulcerative Colitis. <i>Clinical Gastroenterology and Hepatology</i> , <b>2017</b> , 15, 1154-1161.e1	6.9	6
235	Impact of Treatment-Related Beliefs on Medication Adherence in Immune-Mediated Inflammatory Diseases: Results of the Global ALIGN Study. <i>Advances in Therapy</i> , <b>2017</b> , 34, 91-108	4.1	37
234	Systematic review with meta-analysis: comparative efficacy of immunosuppressants and biologics for reducing hospitalisation and surgery in Crohn's disease and ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2017</b> , 45, 3-13	6.1	127
233	Patient Perspectives on Biosimilars: A Survey by the European Federation of Crohn's and Ulcerative Colitis Associations. <i>Journal of Crohn's and Colitis</i> , <b>2017</b> , 11, 128-133	1.5	64
232	Patient-reported Outcomes in a French Nationwide Survey of Inflammatory Bowel Disease Patients. <i>Journal of Crohn's and Colitis</i> , <b>2017</b> , 11, 165-174	1.5	74

231	3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn's Disease 2016: Part 1: Diagnosis and Medical Management. <i>Journal of Crohn's and Colitis</i> , <b>2017</b> , 11, 3-25	1.5	1087
230	Cost-effectiveness of drug monitoring of anti-TNF therapy in inflammatory bowel disease and rheumatoid arthritis: a systematic review. <i>Journal of Gastroenterology</i> , <b>2017</b> , 52, 19-25	6.9	43
229	Insight into the role of TSLP in inflammatory bowel diseases. <i>Autoimmunity Reviews</i> , <b>2017</b> , 16, 55-63	13.6	26
228	Biosimilars in IBD: from theory to practice. <i>Nature Reviews Gastroenterology and Hepatology</i> , <b>2017</b> , 14, 22-31	24.2	66
227	Management Strategies to Improve Outcomes of Patients With Inflammatory Bowel Diseases. <i>Gastroenterology</i> , <b>2017</b> , 152, 351-361.e5	13.3	153
226	Effects of concomitant immunomodulators on the pharmacokinetics, efficacy and safety of adalimumab in patients with Crohn's disease or ulcerative colitis who had failed conventional therapy. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2017</b> , 45, 50-62	6.1	42
225	DOP078 Pharmacology and safety of etrasimod (APD334), an oral, potent, next-generation, selective S1P receptor modulator. <i>Journal of Crohn's and Colitis</i> , <b>2017</b> , 11, S72-S72	1.5	3
224	P369 Safety and lymphocyte-lowering properties of etrasimod (APD334), an oral, potent, next-generation, selective S1P receptor modulator, after dose escalation in healthy volunteers. <i>Journal of Crohn's and Colitis</i> , <b>2017</b> , 11, S265-S266	1.5	2
223	PDE4 Inhibition and Inflammatory Bowel Disease: A Novel Therapeutic Avenue. <i>International Journal of Molecular Sciences</i> , <b>2017</b> , 18,	6.3	27
222	Impact of Treatment-Related Beliefs on Medication Adherence in Immune-Mediated Inflammatory Diseases: Results of the Global ALIGN Study <b>2017</b> , 34, 91		1
221	Accuracy of Diffusion-weighted Magnetic Resonance Colonography in Assessing Mucosal Healing and the Treatment Response in Patients with Ulcerative Colitis. <i>Journal of Crohn's and Colitis</i> , <b>2017</b> , 11, 716-723	1.5	12
220	Iron deficiency anaemia. <i>Lancet, The</i> , <b>2016</b> , 387, 907-16	40	611
219	Defining Disease Severity in Inflammatory Bowel Diseases: Current and Future Directions. <i>Clinical Gastroenterology and Hepatology</i> , <b>2016</b> , 14, 348-354.e17	6.9	217
218	An index with improved diagnostic accuracy for the diagnosis of Crohn's disease derived from the Lennard-Jones criteria. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2016</b> , 44, 601-11	6.1	1
217	Systematic review: outcomes and post-operative complications following colectomy for ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2016</b> , 44, 807-16	6.1	78
216	Implementation of the French national consensus for the management of ulcerative colitis into clinical practice. <i>Digestive and Liver Disease</i> , <b>2016</b> , 48, 1405-1409	3.3	1
215	Effectiveness of budesonide MMX (Cortiment) for the treatment of mild-to-moderate active ulcerative colitis: study protocol for a prospective multicentre observational cohort study. <i>BMJ Open Gastroenterology</i> , <b>2016</b> , 3, e000092	3.9	7
214	Interpreting Registrational Clinical Trials of Biological Therapies in Adults with Inflammatory Bowel Diseases. <i>Inflammatory Bowel Diseases</i> , <b>2016</b> , 22, 2711-2723	4.5	9

213	Diagnostic Delay Is Associated with a Greater Risk of Early Surgery in a French Cohort of Crohn's Disease Patients. <i>Digestive Diseases and Sciences</i> , <b>2016</b> , 61, 3278-3284	4	25
212	Considerations, challenges and future of anti-TNF therapy in treating inflammatory bowel disease. <i>Expert Opinion on Biological Therapy</i> , <b>2016</b> , 16, 1277-90	5.4	30
211	Natural History of Crohn's Disease in Elderly Patients Diagnosed Over the Age of 70 Years: A Population-Based Study. <i>Inflammatory Bowel Diseases</i> , <b>2016</b> , 22, 1698-707	4.5	16
210	Preventing Collateral Damage in Crohn's Disease: The Lhann Index. <i>Journal of Crohn's and Colitis</i> , <b>2016</b> , 10, 495-500	1.5	15
209	Cancer Immunotherapy with Anti-CTLA-4 Monoclonal Antibodies Induces an Inflammatory Bowel Disease. <i>Journal of Crohn's and Colitis</i> , <b>2016</b> , 10, 395-401	1.5	184
208	A safety assessment of anti-tumor necrosis factor alpha therapy for treatment of Crohn's disease. <i>Expert Opinion on Drug Safety</i> , <b>2016</b> , 15, 493-501	4.1	26
207	Methotrexate Is Not Superior to Placebo for Inducing Steroid-Free Remission, but Induces Steroid-Free Clinical Remission in a Larger Proportion of Patients With Ulcerative Colitis. <i>Gastroenterology</i> , <b>2016</b> , 150, 380-8.e4	13.3	85
206	Treatment satisfaction, preferences and perception gaps between patients and physicians in the ulcerative colitis CARES study: A real world-based study. <i>Digestive and Liver Disease</i> , <b>2016</b> , 48, 601-7	3.3	21
205	NOD2 gene variant is a risk factor for postoperative complications in patients with Crohn's disease: A genetic association study. <i>Surgery</i> , <b>2016</b> , 160, 74-80	3.6	11
204	Conditions of prescription of anti-TNF agents in newly treated patients with inflammatory bowel disease in France (2011-2013). <i>Digestive and Liver Disease</i> , <b>2016</b> , 48, 620-5	3.3	15
203	Mechanisms behind efficacy of tumor necrosis factor inhibitors in inflammatory bowel diseases. <i>Pharmacology &amp; Therapeutics</i> , <b>2016</b> , 159, 110-9	13.9	62
202	Immunomodulators for the treatment of Crohn's disease in adults: optimal use and prospects for future drug treatments. <i>Expert Review of Clinical Immunology</i> , <b>2016</b> , 12, 741-9	5.1	1
201	Early Combined Immunosuppression in Crohn's Disease: Acting Rather Than REACTing. <i>Gastroenterology</i> , <b>2016</b> , 150, 1040-1	13.3	3
200	Burden of disease and patient-reported outcomes in patients with moderate to severe ulcerative colitis in the last 12 months - Multicenter European cohort study. <i>Digestive and Liver Disease</i> , <b>2016</b> , 48, 592-600	3.3	24
199	Infliximab Reduces Endoscopic, but Not Clinical, Recurrence of Crohn's Disease After Ileocolonic Resection. <i>Gastroenterology</i> , <b>2016</b> , 150, 1568-1578	13.3	171
198	Pharmacokinetics of Infliximab and Reduction of Treatment for Inflammatory Bowel Diseases. <i>Digestive Diseases and Sciences</i> , <b>2016</b> , 61, 990-5	4	7
197	Effectiveness Research in Inflammatory Bowel Disease: A Necessity and a Methodological Challenge. <i>Journal of Crohn's and Colitis</i> , <b>2016</b> , 10, 1096-102	1.5	22
196	Risk of Incident Cancer in Inflammatory Bowel Disease Patients Starting Anti-TNF Therapy While Having Recent Malignancy. <i>Inflammatory Bowel Diseases</i> , <b>2016</b> , 22, 1362-9	4.5	13

195	IOIBD technical review on endoscopic indices for Crohn's disease clinical trials. <i>Gut</i> , <b>2016</b> , 65, 1447-55	19.2	102
194	Subcutaneous Ustekinumab Provides Clinical Benefit for Two-Thirds of Patients With Crohn's Disease Refractory to Anti-Tumor Necrosis Factor Agents. <i>Clinical Gastroenterology and Hepatology</i> , <b>2016</b> , 14, 242-50.e1-2	6.9	135
193	Self-medication with steroids in inflammatory bowel disease. <i>Digestive and Liver Disease</i> , <b>2016</b> , 48, 23-6	3.3	7
192	Biosimilaires et maladies inflammatoires chroniques de l'intestin. <i>HEGEL - HEpato-GastroEntérologie Libérale</i> , <b>2016</b> , N° 1, 25-30	0.1	
191	Patients' knowledge and fear of colorectal cancer risk in inflammatory bowel disease. <i>Journal of Digestive Diseases</i> , <b>2016</b> , 17, 383-91	3.3	10
190	Excess risk of urinary tract cancers in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2016</b> , 43, 252-61	6.1	77
189	Review article: the natural history of paediatric-onset ulcerative colitis in population-based studies. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2016</b> , 43, 346-55	6.1	45
188	Anti-TNF Monotherapy for Crohn's Disease: a 13-year Multicentre Experience. <i>Journal of Crohn's and Colitis</i> , <b>2016</b> , 10, 516-24	1.5	28
187	French national consensus clinical guidelines for the management of ulcerative colitis. <i>Digestive and Liver Disease</i> , <b>2016</b> , 48, 726-33	3.3	14
186	Cancer and inflammatory bowel disease in the elderly. <i>Digestive and Liver Disease</i> , <b>2016</b> , 48, 1105-11	3.3	23
185	Cumulative Length of Bowel Resection in a Population-Based Cohort of Patients With Crohn's Disease. <i>Clinical Gastroenterology and Hepatology</i> , <b>2016</b> , 14, 1439-44	6.9	9
184	Effectiveness and Safety of Vedolizumab Induction Therapy for Patients With Inflammatory Bowel Disease. <i>Clinical Gastroenterology and Hepatology</i> , <b>2016</b> , 14, 1593-1601.e2	6.9	141
183	Current evidence supporting mucosal healing and deep remission as important treatment goals for inflammatory bowel disease. <i>Expert Review of Gastroenterology and Hepatology</i> , <b>2016</b> , 10, 915-27	4.2	56
182	Intravenous Versus Oral Iron for the Treatment of Anemia in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. <i>Medicine (United States)</i> , <b>2016</b> , 95, e2308	1.8	51
181	Reply to: Dr Macaluso's Letter. <i>Journal of Crohn's and Colitis</i> , <b>2016</b> , 10, 1452	1.5	
180	Biologic Therapies and Risk of Infection and Malignancy in Patients With Inflammatory Bowel Disease: A Systematic Review and Network Meta-analysis. <i>Clinical Gastroenterology and Hepatology</i> , <b>2016</b> , 14, 1385-1397.e10	6.9	219
179	Crohn's Disease Activity and Concomitant Immunosuppressants Affect the Risk of Serious and Opportunistic Infections in Patients Treated With Adalimumab. <i>American Journal of Gastroenterology</i> , <b>2016</b> , 111, 1806-1815	0.7	48
178	Cancer in Elderly Onset Inflammatory Bowel Disease: A Population-Based Study. <i>American Journal of Gastroenterology</i> , <b>2016</b> , 111, 1428-1436	0.7	44

177	The Crohn's Disease-Ulcerative Colitis Clinical Appraisal Update: Emerging Trends in Clinical Practice. <i>Clinical Gastroenterology and Hepatology</i> , <b>2016</b> , 14, e121-2	6.9	2
176	Magnetic resonance enterography is feasible and reliable in multicenter clinical trials in patients with Crohn's disease, and may help select subjects with active inflammation. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2016</b> , 43, 61-72	6.1	47
175	Letter: histological assessment of disease activity in ulcerative colitis--the problem of score evaluation and validation; authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2016</b> , 43, 439	6.1	1
174	Tralokinumab for moderate-to-severe UC: a randomised, double-blind, placebo-controlled, phase IIa study. <i>Gut</i> , <b>2015</b> , 64, 243-9	19.2	113
173	Clinical practice guidelines for the medical management of nonhospitalized ulcerative colitis: the Toronto consensus. <i>Gastroenterology</i> , <b>2015</b> , 148, 1035-1058.e3	13.3	251
172	An endoscopic Mayo score of 0 is associated with a lower risk of colectomy than a score of 1 in ulcerative colitis. <i>Gut</i> , <b>2015</b> , 64, 1181-2	19.2	42
171	Detection of Dysplasia or Cancer in 3.5% of Patients With Inflammatory Bowel Disease and Colonic Strictures. <i>Clinical Gastroenterology and Hepatology</i> , <b>2015</b> , 13, 1770-5	6.9	62
170	Cumulative incidence of, risk factors for, and outcome of dermatological complications of anti-TNF therapy in inflammatory bowel disease: a 14-year experience. <i>American Journal of Gastroenterology</i> , <b>2015</b> , 110, 1186-96	0.7	78
169	Combination of C-reactive protein, infliximab trough levels, and stable but not transient antibodies to infliximab are associated with loss of response to infliximab in inflammatory bowel disease. <i>Journal of Crohn's and Colitis</i> , <b>2015</b> , 9, 525-31	1.5	65
168	Effects of Concomitant Immunomodulator Therapy on Efficacy and Safety of Anti-Tumor Necrosis Factor Therapy for Crohn's Disease: A Meta-analysis of Placebo-controlled Trials. <i>Clinical Gastroenterology and Hepatology</i> , <b>2015</b> , 13, 2233-40.e1-2; quiz e177-8	6.9	92
167	745 Methotrexate for Corticosteroid-Dependent Ulcerative Colitis: Results of a Placebo Randomized Controlled Trial. <i>Gastroenterology</i> , <b>2015</b> , 148, S-140	13.3	8
166	Photodynamic therapy as a new treatment modality for inflammatory and infectious conditions. <i>Expert Review of Clinical Immunology</i> , <b>2015</b> , 11, 637-57	5.1	35
165	Vaccination and Risk for Developing Inflammatory Bowel Disease: A Meta-Analysis of Case-Control and Cohort Studies. <i>Clinical Gastroenterology and Hepatology</i> , <b>2015</b> , 13, 1405-15.e1; quiz e130	6.9	15
164	Clinical trials in ulcerative colitis: a historical perspective. <i>Journal of Crohn's and Colitis</i> , <b>2015</b> , 9, 580-8	1.5	35
163	Biosimilar infliximab for inflammatory bowel disease: from concepts to clinical practice. Case study illustrated with CT-P13. <i>Expert Review of Gastroenterology and Hepatology</i> , <b>2015</b> , 9 Suppl 1, 5-15	4.2	5
162	Keratoconus in Inflammatory Bowel Disease Patients: A Cross-sectional Study. <i>Journal of Crohn's and Colitis</i> , <b>2015</b> , 9, 1108-12	1.5	6
161	Systematic review: the financial burden of surgical complications in patients with ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2015</b> , 41, 1066-78	6.1	22
160	Benefit of Earlier Anti-TNF Treatment on IBD Disease Complications?. <i>Journal of Crohn's and Colitis</i> , <b>2015</b> , 9, 997-1003	1.5	21

159	Biologic agents for IBD: practical insights. <i>Nature Reviews Gastroenterology and Hepatology</i> , <b>2015</b> , 12, 537-45	24.2	196
158	Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target. <i>American Journal of Gastroenterology</i> , <b>2015</b> , 110, 1324-38	0.7	1024
157	Bowel Damage as Assessed by the Lhann Index is Reversible on Anti-TNF Therapy for Crohn's Disease. <i>Journal of Crohn's and Colitis</i> , <b>2015</b> , 9, 633-9	1.5	52
156	Targeting SMAD7 in Crohn's Disease by Mongersen: Therapeutic Revolution Under Way?. <i>Gastroenterology</i> , <b>2015</b> , 149, 1121-3	13.3	4
155	Guidelines on the diagnosis and treatment of iron deficiency across indications: a systematic review. <i>American Journal of Clinical Nutrition</i> , <b>2015</b> , 102, 1585-94	7	150
154	Comparing histological activity indexes in UC. <i>Gut</i> , <b>2015</b> , 64, 1412-8	19.2	103
153	Treat to target: a proposed new paradigm for the management of Crohn's disease. <i>Clinical Gastroenterology and Hepatology</i> , <b>2015</b> , 13, 1042-50.e2	6.9	190
152	Risk of lymphoma in patients with inflammatory bowel disease treated with azathioprine and 6-mercaptopurine: a meta-analysis. <i>Clinical Gastroenterology and Hepatology</i> , <b>2015</b> , 13, 847-58.e4; quiz e48-50	6.9	246
151	Letter: infliximab de-escalation based on trough levels in patients with inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2015</b> , 42, 939-40	6.1	16
150	Cost savings of anti-TNF therapy using a test-based strategy versus an empirical dose escalation in Crohn's disease patients who lose response to infliximab. <i>Journal of Market Access &amp; Health Policy</i> , <b>2015</b> , 3,	3.7	11
149	Histologic features predicting postoperative Crohn's disease recurrence. <i>Inflammatory Bowel Diseases</i> , <b>2015</b> , 21, 468-75	4.5	34
148	A Systematic Review of Factors Associated with Non-Adherence to Treatment for Immune-Mediated Inflammatory Diseases. <i>Advances in Therapy</i> , <b>2015</b> , 32, 983-1028	4.1	101
147	Impact of the early use of immunomodulators or TNF antagonists on bowel damage and surgery in Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2015</b> , 42, 977-89	6.1	67
146	Systematic review and meta-analysis: opportunistic infections and malignancies during treatment with anti-integrin antibodies in inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2015</b> , 41, 1227-36	6.1	51
145	Review article: the histological assessment of disease activity in ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2015</b> , 42, 957-67	6.1	41
144	Beliefs and behaviour about smoking among inflammatory bowel disease patients. <i>European Journal of Gastroenterology and Hepatology</i> , <b>2015</b> , 27, 797-803	2.2	11
143	Impact of immunosuppressive therapy on hepatitis B vaccination in inflammatory bowel diseases. <i>European Journal of Gastroenterology and Hepatology</i> , <b>2015</b> , 27, 877-81	2.2	26
142	Clinical remission as defined by the Mayo Score: do we deceive ourselves?. <i>Inflammatory Bowel Diseases</i> , <b>2015</b> , 21, E2-3	4.5	3

141	IgE antibodies and skin tests in immediate hypersensitivity reactions to infliximab in inflammatory bowel disease: impact on infliximab retreatment. <i>European Journal of Gastroenterology and Hepatology</i> , <b>2015</b> , 27, 1200-8	2.2	17
140	Is Diffusion-weighted Magnetic Resonance Imaging for Assessing Crohn's Disease Ready for Prime Time? Experience with the Nancy Score. <i>Inflammatory Bowel Diseases</i> , <b>2015</b> , 21, E25	4.5	4
139	Interventions to Improve Adherence in Patients with Immune-Mediated Inflammatory Disorders: A Systematic Review. <i>PLoS ONE</i> , <b>2015</b> , 10, e0145076	3.7	31
138	Development of Red Flags Index for Early Referral of Adults with Symptoms and Signs Suggestive of Crohn's Disease: An IOIBD Initiative. <i>Journal of Crohn's and Colitis</i> , <b>2015</b> , 9, 601-6	1.5	47
137	The POCER Trial: Bet on Active Care. <i>Gastroenterology</i> , <b>2015</b> , 148, 1474-5	13.3	3
136	CARD8 gene variant is a risk factor for recurrent surgery in patients with Crohn's disease. <i>Digestive and Liver Disease</i> , <b>2015</b> , 47, 938-42	3.3	10
135	Predicting future disease course in Crohn's disease by colonoscopy or magnetic resonance: which is the crystal ball?. <i>Gut</i> , <b>2015</b> , 64, 1347-8	19.2	2
134	Ileal ulcers not responding to infliximab therapy: think about intestinal ganglioneuromatosis. <i>Digestive and Liver Disease</i> , <b>2015</b> , 47, 257-8	3.3	1
133	Efficacy of tumour necrosis factor antagonists on remission, colectomy and hospitalisations in ulcerative colitis: Meta-analysis of placebo-controlled trials. <i>Digestive and Liver Disease</i> , <b>2015</b> , 47, 356-64	3.3	29
132	Prevention and treatment of postoperative Crohn's disease recurrence with anti-TNF therapy: a meta-analysis of controlled trials. <i>Digestive and Liver Disease</i> , <b>2015</b> , 47, 191-6	3.3	39
131	Current, new and future biological agents on the horizon for the treatment of inflammatory bowel diseases. <i>Therapeutic Advances in Gastroenterology</i> , <b>2015</b> , 8, 66-82	4.7	92
130	Defining Severity in Inflammatory Bowel Disease. <i>Gastroenterology and Hepatology</i> , <b>2015</b> , 11, 474-6	0.7	
129	Natural history of elderly-onset inflammatory bowel disease: a population-based cohort study. <i>Gut</i> , <b>2014</b> , 63, 423-32	19.2	211
128	Systematic review: The epidemiology of the hepatobiliary manifestations in patients with inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2014</b> , 40, 3-15	6.1	76
127	Low serum trough levels are associated with post-surgical recurrence in Crohn's disease patients undergoing prophylaxis with adalimumab. <i>Digestive and Liver Disease</i> , <b>2014</b> , 46, 1043-6	3.3	11
126	Risk of new or recurrent cancer under immunosuppressive therapy in patients with IBD and previous cancer. <i>Gut</i> , <b>2014</b> , 63, 1416-23	19.2	94
125	Development of an algorithm incorporating pharmacokinetics of adalimumab in inflammatory bowel diseases. <i>American Journal of Gastroenterology</i> , <b>2014</b> , 109, 1250-6	0.7	143
124	Systematic review with meta-analysis: malignancies with anti-tumour necrosis factor- $\alpha$ therapy in inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2014</b> , 39, 447-58	6.1	112

123	Anti-tumor necrosis factor- $\alpha$ monotherapy versus combination therapy with an immunomodulator in IBD. <i>Gastroenterology Clinics of North America</i> , <b>2014</b> , 43, 441-56	4.4	17
122	Systematic review: Monotherapy with antitumour necrosis factor $\alpha$ agents versus combination therapy with an immunosuppressive for IBD. <i>Gut</i> , <b>2014</b> , 63, 1843-53	19.2	86
121	Extra-intestinal malignancies in inflammatory bowel disease: results of the 3rd ECCO Pathogenesis Scientific Workshop (III). <i>Journal of Crohn's and Colitis</i> , <b>2014</b> , 8, 31-44	1.5	111
120	Histologic remission: the ultimate therapeutic goal in ulcerative colitis?. <i>Clinical Gastroenterology and Hepatology</i> , <b>2014</b> , 12, 929-34.e2	6.9	120
119	Improving quality of care in inflammatory bowel disease: what changes can be made today?. <i>Journal of Crohn's and Colitis</i> , <b>2014</b> , 8, 919-26	1.5	55
118	Tolerability of one hour 10mg/kg infliximab infusions in inflammatory bowel diseases: a prospective multicenter cohort study. <i>Journal of Crohn's and Colitis</i> , <b>2014</b> , 8, 161-5	1.5	14
117	Patient-reported outcomes as primary end points in clinical trials of inflammatory bowel disease. <i>Clinical Gastroenterology and Hepatology</i> , <b>2014</b> , 12, 1246-56.e6	6.9	157
116	Thromboembolic events and cardiovascular mortality in inflammatory bowel diseases: a meta-analysis of observational studies. <i>Journal of Crohn's and Colitis</i> , <b>2014</b> , 8, 469-79	1.5	101
115	Association between pharmacokinetics of adalimumab and mucosal healing in patients with inflammatory bowel diseases. <i>Clinical Gastroenterology and Hepatology</i> , <b>2014</b> , 12, 80-84.e2	6.9	215
114	Clinical trials in luminal Crohn's disease: a historical perspective. <i>Journal of Crohn's and Colitis</i> , <b>2014</b> , 8, 1339-50	1.5	20
113	Thiopurines and risk of colorectal neoplasia in patients with inflammatory bowel disease: a meta-analysis. <i>Clinical Gastroenterology and Hepatology</i> , <b>2014</b> , 12, 1793-1800.e1	6.9	49
112	Treatment algorithms in Crohn's - up, down or something else?. <i>Baillieres Best Practice and Research in Clinical Gastroenterology</i> , <b>2014</b> , 28, 473-83	2.5	25
111	Biological agents for moderately to severely active ulcerative colitis: a systematic review and network meta-analysis. <i>Annals of Internal Medicine</i> , <b>2014</b> , 160, 704-11	8	158
110	Scores endoscopiques des maladies inflammatoires chroniques de l'intestin. <i>Acta Endoscopica</i> , <b>2014</b> , 44, 408-409		
109	Are we improving disease outcomes in IBD? A view from the epidemiology side. <i>Gut</i> , <b>2014</b> , 63, 1529-30	19.2	9
108	Factors associated with pregnancy outcome in anti-TNF treated women with inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2014</b> , 40, 363-73	6.1	65
107	The prevalence of inflammatory sacroiliitis assessed on magnetic resonance imaging of inflammatory bowel disease: a retrospective study performed on 186 patients. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2014</b> , 39, 957-62	6.1	36
106	IBD in 2013: enriching the therapeutic armamentarium for IBD. <i>Nature Reviews Gastroenterology and Hepatology</i> , <b>2014</b> , 11, 84-6	24.2	5

105	Pharmacokinetics of adalimumab in inflammatory bowel diseases: a systematic review and meta-analysis. <i>Inflammatory Bowel Diseases</i> , <b>2014</b> , 20, 1288-95	4.5	79
104	Clinical disease activity, C-reactive protein normalisation and mucosal healing in Crohn's disease in the SONIC trial. <i>Gut</i> , <b>2014</b> , 63, 88-95	19.2	325
103	Increased risk of acute myeloid leukemias and myelodysplastic syndromes in patients who received thiopurine treatment for inflammatory bowel disease. <i>Clinical Gastroenterology and Hepatology</i> , <b>2014</b> , 12, 1324-9	6.9	61
102	Diagnostic delay in a French cohort of Crohn's disease patients. <i>Journal of Crohn's and Colitis</i> , <b>2014</b> , 8, 964-9	1.5	43
101	Management of inflammatory bowel disease in France: a nationwide survey among private gastroenterologists. <i>Digestive and Liver Disease</i> , <b>2014</b> , 46, 675-81	3.3	11
100	Azathioprine in early Crohn's disease: time to revisit patient selection and end points for clinical trials and/or azathioprine efficacy?. <i>Gastroenterology</i> , <b>2014</b> , 146, 867-8	13.3	5
99	Deep remission in Crohn's disease: is it the end of the placebo effect?. <i>Clinical Gastroenterology and Hepatology</i> , <b>2014</b> , 12, 347	6.9	10
98	Microscopic features of colorectal neoplasia in inflammatory bowel diseases. <i>World Journal of Gastroenterology</i> , <b>2014</b> , 20, 3164-72	5.6	28
97	Dietary beliefs and behavior among inflammatory bowel disease patients. <i>Inflammatory Bowel Diseases</i> , <b>2013</b> , 19, 66-72	4.5	121
96	Deep remission in inflammatory bowel disease: looking beyond symptoms. <i>Current Gastroenterology Reports</i> , <b>2013</b> , 15, 315	5	91
95	979 Impact of Concomitant Immunomodulator Treatment on Efficacy and Safety of Anti-TNF Therapy in Crohn's Disease: A Meta-Analysis of Placebo Controlled Trials With Individual Patient-Level Data. <i>Gastroenterology</i> , <b>2013</b> , 144, S-179	13.3	8
94	Tolerability of one hour 10 mg/kg infliximab infusions in patients with inflammatory bowel disease. <i>Journal of Crohn's and Colitis</i> , <b>2013</b> , 7, 129-33	1.5	7
93	Bacterial sensor triggering receptor expressed on myeloid cells-2 regulates the mucosal inflammatory response. <i>Gastroenterology</i> , <b>2013</b> , 144, 346-356.e3	13.3	37
92	Disease-modifying anti-inflammatory bowel disease drugs (DMAIDs): the missing term in the literature. <i>American Journal of Gastroenterology</i> , <b>2013</b> , 108, 859-60	0.7	15
91	Preventing postoperative recurrence in Crohn's disease: what does the future hold?. <i>Drugs</i> , <b>2013</b> , 73, 1749-59	12.1	21
90	Review article: biosimilars are the next generation of drugs for liver and gastrointestinal diseases. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2013</b> , 38, 914-24	6.1	43
89	Diagnostic delay in Crohn's disease is associated with a complicated disease course and increased operation rate. <i>American Journal of Gastroenterology</i> , <b>2013</b> , 108, 1744-53; quiz 1754	0.7	128
88	5-Aminosalicylates and renal function monitoring in inflammatory bowel disease: a nationwide survey. <i>Journal of Crohn's and Colitis</i> , <b>2013</b> , 7, 551-5	1.5	11

87	Preoperative use of anti-TNF therapy and postoperative complications in inflammatory bowel diseases: a meta-analysis. <i>Journal of Crohn's and Colitis</i> , <b>2013</b> , 7, 853-67	1.5	142
86	Ocular symptoms are not predictive of ophthalmologic inflammation in inflammatory bowel disease. <i>Digestive and Liver Disease</i> , <b>2013</b> , 45, 195-9	3.3	12
85	Development and validation of a patient-reported disability measurement tool for patients with inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2013</b> , 37, 438-44	6.1	34
84	Epidemiology of inflammatory bowel diseases: new insights from a French population-based registry (EPIMAD). <i>Digestive and Liver Disease</i> , <b>2013</b> , 45, 89-94	3.3	128
83	Endoscopie et MICI : pourquoi mettre à jour les recommandations de la SFED ?. <i>Acta Endoscopica</i> , <b>2013</b> , 43, 109-109		
82	Long-term outcome of perianal fistulizing Crohn's disease treated with infliximab. <i>Clinical Gastroenterology and Hepatology</i> , <b>2013</b> , 11, 975-81.e1-4	6.9	132
81	Imaging techniques for assessment of inflammatory bowel disease: joint ECCO and ESGAR evidence-based consensus guidelines. <i>Journal of Crohn's and Colitis</i> , <b>2013</b> , 7, 556-85	1.5	438
80	Opportunistic infections with anti-tumor necrosis factor- $\alpha$ therapy in inflammatory bowel disease: meta-analysis of randomized controlled trials. <i>American Journal of Gastroenterology</i> , <b>2013</b> , 108, 1268-76	0.7	247
79	First-line therapy in adult Crohn's disease: who should receive anti-TNF agents?. <i>Nature Reviews Gastroenterology and Hepatology</i> , <b>2013</b> , 10, 345-51	24.2	46
78	Colonoscopic perforations in inflammatory bowel disease: a retrospective study in a French referral centre. <i>Digestive and Liver Disease</i> , <b>2013</b> , 45, 569-72	3.3	26
77	Risk of colorectal high-grade dysplasia and cancer in a prospective observational cohort of patients with inflammatory bowel disease. <i>Gastroenterology</i> , <b>2013</b> , 145, 166-175.e8	13.3	228
76	Janus kinase inhibition with tofacitinib: changing the face of inflammatory bowel disease treatment. <i>Current Drug Targets</i> , <b>2013</b> , 14, 1385-91	3	31
75	Mortality and cancer in pediatric-onset inflammatory bowel disease: a population-based study. <i>American Journal of Gastroenterology</i> , <b>2013</b> , 108, 1647-53	0.7	48
74	Endoscopy in inflammatory bowel disease: recommendations from the IBD Committee of the French Society of Digestive Endoscopy (SFED). <i>Endoscopy</i> , <b>2013</b> , 45, 936-43	3.4	15
73	Therapeutic drug monitoring of infliximab and mucosal healing in inflammatory bowel disease: a prospective study. <i>Inflammatory Bowel Diseases</i> , <b>2013</b> , 19, 2568-76	4.5	170
72	Moving towards disease modification in inflammatory bowel disease therapy. <i>Current Opinion in Gastroenterology</i> , <b>2013</b> , 29, 397-404	3	63
71	Leukoapheresis in Crohn's disease: the final curtain?. <i>Gut</i> , <b>2013</b> , 62, 487-8	19.2	0
70	Impact of mucosal healing on long-term outcomes in ulcerative colitis treated with infliximab: a multicenter experience. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2013</b> , 37, 998-1004	6.1	84

69	The effect of immune therapy on surgical site infection following Crohn's Disease resection. <i>British Journal of Surgery</i> , <b>2013</b> , 100, 1089-93	5.3	66
68	Letter: fatigue, a growing concern in inflammatory bowel diseases. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2013</b> , 38, 442	6.1	
67	The extra burden of infliximab infusions in inflammatory bowel disease. <i>Inflammatory Bowel Diseases</i> , <b>2013</b> , 19, 2464-7	4.5	15
66	Adherence to anti-TNF therapy in inflammatory bowel diseases: a systematic review. <i>Inflammatory Bowel Diseases</i> , <b>2013</b> , 19, 1528-33	4.5	98
65	Microscopic features for initial diagnosis and disease activity evaluation in inflammatory bowel disease. <i>Inflammatory Bowel Diseases</i> , <b>2013</b> , 19, 1745-52	4.5	16
64	Submucosal plexitis as a predictor of postoperative surgical recurrence in Crohn's disease. <i>Inflammatory Bowel Diseases</i> , <b>2013</b> , 19, 1654-61	4.5	28
63	Evolving definitions of remission in Crohn's disease. <i>Inflammatory Bowel Diseases</i> , <b>2013</b> , 19, 1645-53	4.5	42
62	Advances in the treatment of ulcerative colitis. <i>Gastroenterology and Hepatology</i> , <b>2013</b> , 9, 827-9	0.7	
61	Methotrexate for psoriasiform lesions associated with anti-tumour necrosis factor therapy in inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2012</b> , 35, 1175-80	6.1	18
60	Perianal Crohn's disease findings other than fistulas in a population-based cohort. <i>Inflammatory Bowel Diseases</i> , <b>2012</b> , 18, 43-8	4.5	26
59	Can elderly people be treated safely with anti-TNF agents?. <i>Inflammatory Bowel Diseases</i> , <b>2012</b> , 18, 594-5	4.5	3
58	Treatment of extraintestinal manifestations in inflammatory bowel disease. <i>Digestion</i> , <b>2012</b> , 86 Suppl 1, 28-35	3.6	47
57	Letter: anti-TNFs and psoriasis [Friends or foes? Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2012</b> , 36, 498-498	6.1	
56	La cicatrisation muqueuse dans les MICI : pourquoi, quand et comment l'obtenir ?. <i>Acta Endoscopica</i> , <b>2012</b> , 42, 237-238		
55	Development of the Paris definition of early Crohn's disease for disease-modification trials: results of an international expert opinion process. <i>American Journal of Gastroenterology</i> , <b>2012</b> , 107, 1770-6	0.7	76
54	Implementing changes in clinical practice to improve the management of Crohn's disease. <i>Journal of Crohn's and Colitis</i> , <b>2012</b> , 6 Suppl 2, S235-42	1.5	16
53	Identification of areas of functioning and disability addressed in inflammatory bowel disease-specific patient reported outcome measures. <i>Journal of Crohn's and Colitis</i> , <b>2012</b> , 6, 507-17	1.5	21
52	Diagnosis, prevention and treatment of postoperative Crohn's disease recurrence. <i>Digestive and Liver Disease</i> , <b>2012</b> , 44, 453-60	3.3	44

51	Plasma soluble triggering receptor expressed on myeloid cells-1 in Crohn's disease. <i>Digestive and Liver Disease</i> , <b>2012</b> , 44, 466-70	3.3	6
50	Surgery in a population-based cohort of Crohn's disease from Olmsted County, Minnesota (1970-2004). <i>American Journal of Gastroenterology</i> , <b>2012</b> , 107, 1693-701	0.7	199
49	Mucosal healing with anti-TNF antibodies. <i>Digestion</i> , <b>2012</b> , 86 Suppl 1, 16-22	3.6	15
48	Risk of colorectal cancer in patients with ulcerative colitis: a meta-analysis of population-based cohort studies. <i>Clinical Gastroenterology and Hepatology</i> , <b>2012</b> , 10, 639-45	6.9	549
47	Deep remission: a new concept?. <i>Digestive Diseases</i> , <b>2012</b> , 30 Suppl 3, 107-11	3.2	32
46	Clinical risk factors for complicated disease: how reliable are they?. <i>Digestive Diseases</i> , <b>2012</b> , 30 Suppl 3, 67-72	3.2	52
45	Urinary tract infections in hospitalized inflammatory bowel disease patients: a 10-year experience. <i>Inflammatory Bowel Diseases</i> , <b>2012</b> , 18, 697-702	4.5	15
44	Effects of immunosuppression on immune response to pneumococcal vaccine in inflammatory bowel disease: a prospective study. <i>Inflammatory Bowel Diseases</i> , <b>2012</b> , 18, 1042-7	4.5	120
43	Incidence of and impact of medications on colectomy in newly diagnosed ulcerative colitis in the era of biologics. <i>Inflammatory Bowel Diseases</i> , <b>2012</b> , 18, 1641-6	4.5	49
42	Ulcerative colitis as a progressive disease: the forgotten evidence. <i>Inflammatory Bowel Diseases</i> , <b>2012</b> , 18, 1356-63	4.5	133
41	Excess primary intestinal lymphoproliferative disorders in patients with inflammatory bowel disease. <i>Inflammatory Bowel Diseases</i> , <b>2012</b> , 18, 2063-71	4.5	77
40	Colorectal cancer in inflammatory bowel diseases: a population-based study (1976-2008). <i>Inflammatory Bowel Diseases</i> , <b>2012</b> , 18, 2247-51	4.5	40
39	Stopping infliximab in Crohn's disease: still an ongoing STORI. <i>Inflammatory Bowel Diseases</i> , <b>2012</b> , 18, 2201-2	4.5	6
38	Complementary and alternative medicine in inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2012</b> , 35, 619-20	6.1	1
37	Review article: the natural history of postoperative Crohn's disease recurrence. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2012</b> , 35, 625-33	6.1	215
36	Development of the first disability index for inflammatory bowel disease based on the international classification of functioning, disability and health. <i>Gut</i> , <b>2012</b> , 61, 241-7	19.2	216
35	Mesenteric fat as a source of C reactive protein and as a target for bacterial translocation in Crohn's disease. <i>Gut</i> , <b>2012</b> , 61, 78-85	19.2	171
34	Risk of melanoma in patients who receive thiopurines for inflammatory bowel disease is not increased. <i>American Journal of Gastroenterology</i> , <b>2012</b> , 107, 1443-4	0.7	28

33	Ulcerative colitis as a sole mucosal disease: another misunderstanding?. <i>Gut</i> , <b>2012</b> , 61, 633	19.2	11
32	Bowel damage assessment in Crohn's disease by magnetic resonance imaging. <i>Current Drug Targets</i> , <b>2012</b> , 13, 1300-7	3	6
31	Results from the 2nd Scientific Workshop of the ECCO. I: Impact of mucosal healing on the course of inflammatory bowel disease. <i>Journal of Crohn's and Colitis</i> , <b>2011</b> , 5, 477-83	1.5	247
30	Increased risk for nonmelanoma skin cancers in patients who receive thiopurines for inflammatory bowel disease. <i>Gastroenterology</i> , <b>2011</b> , 141, 1621-28.e1-5	13.3	337
29	Loss of response and need for adalimumab dose intensification in Crohn's disease: a systematic review. <i>American Journal of Gastroenterology</i> , <b>2011</b> , 106, 674-84	0.7	280
28	Does anti-TNF therapy reduce the requirement for surgery in ulcerative colitis? A systematic review. <i>Current Drug Targets</i> , <b>2011</b> , 12, 1440-7	3	48
27	The use of azathioprine in Crohn's disease during pregnancy and in the post-operative setting: a worldwide survey of experts. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2011</b> , 33, 707-13	6.1	30
26	Review article: remission rates achievable by current therapies for inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2011</b> , 33, 870-9	6.1	111
25	Meta-analysis: hyperhomocysteinaemia in inflammatory bowel diseases. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2011</b> , 34, 1173-84	6.1	73
24	Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47. <i>Nature Genetics</i> , <b>2011</b> , 43, 246-52	36.3	1028
23	Long-term complications, extraintestinal manifestations, and mortality in adult Crohn's disease in population-based cohorts. <i>Inflammatory Bowel Diseases</i> , <b>2011</b> , 17, 471-8	4.5	148
22	Optimizing thiopurine therapy in inflammatory bowel disease. <i>Inflammatory Bowel Diseases</i> , <b>2011</b> , 17, 1428-35	4.5	30
21	Development of the Crohn's disease digestive damage score, the Lhann score. <i>Inflammatory Bowel Diseases</i> , <b>2011</b> , 17, 1415-22	4.5	395
20	Gastroenterology review and perspective: the role of cross-sectional imaging in evaluating bowel damage in Crohn disease. <i>American Journal of Roentgenology</i> , <b>2011</b> , 197, 42-9	5.4	45
19	H1N1 vaccines in a large observational cohort of patients with inflammatory bowel disease treated with immunomodulators and biological therapy. <i>Gut</i> , <b>2011</b> , 60, 456-62	19.2	60
18	Impact of azathioprine and tumour necrosis factor antagonists on the need for surgery in newly diagnosed Crohn's disease. <i>Gut</i> , <b>2011</b> , 60, 930-6	19.2	177
17	Surgery for adult Crohn's disease: what is the actual risk?. <i>Gut</i> , <b>2011</b> , 60, 1178-81	19.2	158
16	Histoire naturelle de la maladie de Crohn <b>2011</b> , 105-114		

15	Infliximab for refractory ulcerative proctitis. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2010</b> , 31, 1178-85	3.1	29
14	What is the patient's perspective: How important are patient-reported outcomes, quality of life and disability?. <i>Digestive Diseases</i> , <b>2010</b> , 28, 463-71	3.2	33
13	Diffusion-weighted magnetic resonance without bowel preparation for detecting colonic inflammation in inflammatory bowel disease. <i>Gut</i> , <b>2010</b> , 59, 1056-65	19.2	203
12	A multicenter experience with infliximab for ulcerative colitis: outcomes and predictors of response, optimization, colectomy, and hospitalization. <i>American Journal of Gastroenterology</i> , <b>2010</b> , 105, 2617-25	0.7	135
11	Early Crohn disease: a proposed definition for use in disease-modification trials. <i>Gut</i> , <b>2010</b> , 59, 141-7	19.2	88
10	Severe skin lesions cause patients with inflammatory bowel disease to discontinue anti-tumor necrosis factor therapy. <i>Clinical Gastroenterology and Hepatology</i> , <b>2010</b> , 8, 1048-55	6.9	127
9	The natural history of adult Crohn's disease in population-based cohorts. <i>American Journal of Gastroenterology</i> , <b>2010</b> , 105, 289-97	0.7	641
8	Predictors of infliximab failure after azathioprine withdrawal in Crohn's disease treated with combination therapy. <i>American Journal of Gastroenterology</i> , <b>2010</b> , 105, 1142-9	0.7	75
7	Clinical implications of mucosal healing for the management of IBD. <i>Nature Reviews Gastroenterology and Hepatology</i> , <b>2010</b> , 7, 15-29	24.2	347
6	Disability in inflammatory bowel diseases: developing ICF Core Sets for patients with inflammatory bowel diseases based on the International Classification of Functioning, Disability, and Health. <i>Inflammatory Bowel Diseases</i> , <b>2010</b> , 16, 15-22	4.5	73
5	Anti-TNF therapy in inflammatory bowel diseases: a huge review. <i>Minerva Gastroenterologica E Dietologica</i> , <b>2010</b> , 56, 233-43	1.6	83
4	Azathioprine and 6-mercaptopurine for the prevention of postoperative recurrence in Crohn's disease: a meta-analysis. <i>American Journal of Gastroenterology</i> , <b>2009</b> , 104, 2089-96	0.7	193
3	Crohn's disease: beyond antagonists of tumour necrosis factor. <i>Lancet, The</i> , <b>2008</b> , 372, 67-81	4.0	80
2	Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials. <i>Clinical Gastroenterology and Hepatology</i> , <b>2008</b> , 6, 644-53	6.9	462
1	Re-Routing Infliximab Therapy: Subcutaneous Infliximab Opens a Path Towards Greater Convenience and Clinical Benefit. <i>Clinical Drug Investigation</i> ,	3.2	